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Abstract 
 
BACKGROUND. Endometriosis is a very common but poorly understood disease. Defined as the 
presence of tissue resembling endometrial glands and stroma found in various locations around the 
body the disease manifests as implants which periodically proliferate and bleed. Our understanding 
of the mechanisms underlying the disease is limited. No methods are available for predicting the 
incidence of endometriosis around the world.  There are many theories concerning the origin of 
endometriosis that contradict and complement each other.  Heritable changes in gene expression 
independent of changes to DNA sequence, often referred to as epigenetics, is being considered as 
one possible mechanism via which endometriosis can develop.   Epigenetics is a relatively new field 
of research that has revolutionised the understanding of complex diseases such as cancer and 
diabetes. 
AIMS AND OBJECTIVES. Firstly, this thesis aims to provide a novel model for predicting the incidence 
of endometriosis based on known epidemiological risk factors. The second aim of this thesis is to 
investigate the involvement of epigenetic mechanisms such as DNA methylation, loss of imprinting 
and aberrant microRNA expression in the aetiology of endometriosis. 
METHODS. For the prediction of endometriosis, data on known epidemiological risk factors for 
endometriosis, including diet and parity, were collected for 121 countries from various international 
databases such as the Food and Agriculture Organisation and World Health Organisation, normalised 
and used to generate a model predicting patterns of endometriosis risk. For the epigenetic study, 
systematic reviews and critical analysis was carried out on the literature concerning DNA 
methylation and transgenerational epigenetic inheritance, as well as other epigenetic mechanisms 
found to be disrupted in endometriosis. Bioinformatic analysis of imprinted gene databases and 
microRNA prediction software was cross referenced with existing microarray data on endometriosis 
to identify novel imprinted genes and microRNAs that may be involved in the aetiology of 
endometriosis. 
RESULTS AND DISCUSSION. The prediction model reveals that the incidence of endometriosis is 
most prevalent in Northern Europe and North America, with the lowest incidences in equatorial 
Africa. Asia and South America appear to be areas of intermediate risk. The incidence of 
endometriosis, predicted from the proposed model, concurs with what limited knowledge currently 
exists concerning the incidence of endometriosis, based on previous epidemiological studies, 
suggesting that it is reliable. This preliminary model provides, for the first time, information about 
endometriosis prevalence outside Europe, America and Australia and presents a basis for a more 
detailed epidemiological investigation into endometriosis.   Analysis of epigenetic data identified the 
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aromatase cycle and estrogen sensitivity in endometriotic cells as having an epigenetic origin. Two 
imprinted genes, ABS4 and BEGAIN, were identified as being disrupted in endometriosis, with the 
potential for epigenetic disruption of IGF-2 in endometriosis also discussed. Numerous microRNAs, 
such as mir-23a and mir-29a, were identified as playing a significant role in the immune system 
dysfunction observed in endometriosis. The evidence for environmentally induced endometriosis 
being transmitted to future generations by epigenetic means is also presented. 
CONCLUSION. A promising new approach for predicting the incidence of endometriosis has been 
developed that can be further developed in the future to improve its predictive accuracy and 
robustness. The combined bioinformatics and genomic data analysis identified aberrations in 
imprinted genes and microRNAs that may play a significant role in the development of 
endometriosis. This provides the basis for future studies exploring these systems that may provide 
novel therapeutic strategies for the treatment of endometriosis. 
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Chapter 1: Introduction 
 
Endometriosis is a complex but very common gynaecological disease, often described as enigmatic 
due an incomplete understanding of the exact aetiology of the disease. Endometriosis is defined as 
the presence of endometrial glandular and stromal cells in extra uterine locations. These 
endometrial cells invade and proliferate forming endometriotic implants. These implants behave like 
normal (eutopic) endometrium, i.e. they proliferate and bleed in conjunction with hormonal cycles. 
The activity of these implants can lead to painful internal scarring, dysfunction of the affected 
organ/s and the formation of inter-organ adhesions.  
 
Endometriosis is most commonly characterised by numerous painful symptoms brought on by the 
activity of the endometriotic implants but is also associated with numerous other symptoms that can 
lower the quality of life of the sufferer. The most common symptoms include dysmenorrhoea 
(painful periods), dyspareunia (painful intercourse), chronic pelvic pain (defined as more than 6 
months of non cyclic pain), abnormal uterine bleeding, and reduced fertility. Less common 
symptoms include chronic fatigue, painful bowel movements (dyschezia), painful urination (dysuria) 
or pain in areas other than the pelvis, such as back, legs or shoulders. There are also numerous 
psychological symptoms, such as depression, that can be associated with endometriosis due to the 
heavy emotional burden of the disease.  
 
Endometriosis is a common disease, it is approximated that endometriosis affects 1 in 10 women of 
reproductive age [1], although estimates range from 5% to 20% of the general population [1]. There 
is some evidence to suggest endometriosis is more common in non-Hispanic Caucasians than 
women of African descent  [2, 3], however studies on the racial differences of endometriosis are 
very few in number. Although endometriosis was previously considered to be a disease that affected 
women approaching middle age, it is now recognised that the disease is diagnosed more frequently 
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in younger women [4]. The symptoms of endometriosis can present as early as the onset of puberty, 
particularly around the time of menarche. However, as patients find it difficult to get their symptoms 
taken seriously and misdiagnosis is common, there are extensive delays in the diagnostic process, 
meaning that the average time for a woman to be diagnosed with endometriosis can be up to 9 
years. There are numerous factors compounding the diagnostic process, foremost of which is the 
heterogeneous nature of its symptoms that can often lead to misdiagnosis. A survey of women from 
the United Kingdom found that 68% of women were initially misdiagnosed, most commonly with 
irritable bowel syndrome [5]. Furthermore, accurate diagnosis can only be achieved via a 
laparoscopy, whereby a camera is inserted into the pelvic cavity for visual assessment of any 
endometriotic implants [6]. The accuracy of this procedure is dependent on factors including the 
quality of the equipment and the skill of the surgeon. This may be the reason that the incidence 
rates of endometriosis are only known for a handful of Western countries, with data on incidence 
from other countries simply non-existent.  
 
Endometriosis is not only a heavy burden for the sufferer, but also in economic terms. The loss of 
work hours caused by illness due to endometriosis is estimated to cost the UK economy over 
£2billion a year [7]. There is also the cost to the National Health Service to take into consideration in 
terms of diagnostic/therapeutic surgeries and medical treatments which may add further billions to 
the total economic cost of endometriosis. A recent study from the USA, for example, found that the 
average cost of an individual surgical procedure ranged from $4,289 to $11,397 depending on its 
nature [8]. Given that many women with endometriosis require multiple surgical procedures it is 
likely endometriosis is extremely costly in economic terms.   
 
Despite increased research into the origin and pathophysiology of endometriosis there are still many 
gaps in our knowledge that needs to be filled. It is therefore imperative to implement new and 
emerging scientific concepts into our understanding of endometriosis.  
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1.1 On the Origin of Endometriosis 
 
How endometriosis arises within the body has been a matter of debate ever since the disease was 
first described over 300 years ago as ‘cysts’ on the organs of the pelvic cavity, and later described in 
detail in 1860 by a physician named Von Rokitansky [9]. However, it wasn’t until 1927 when a 
physician from Albany, New York named John Sampson began formulating his theories on the origin 
of endometriosis that our understanding of the disease began to flourish [10]. Sampson’s pioneering 
work provided the basis for the theory of retrograde menstruation for the origin of endometriosis, 
which is still the most widely accepted theory on how endometriosis arises. 
1.1.1 Retrograde Menstruation  
Sampson postulated that during normal menstruation, menstrual debris including viable eutopic 
endometrial cells, cytokines and growth factors could travel in a retrograde fashion through the 
fallopian tubes and into the pelvic cavity [10], here these cells could invade and proliferate on 
surrounding tissues (Figure 1). This theory is supported by the histological similarity between  
ectopic (endometriotic) tissue and normal (eutopic) endometrial tissue (Figure 2) and the frequent 
occurrence of endometriosis on the organs of the pelvic cavity, such as the uterus, uterosacaral 
ligaments and the ovaries [11]. Additional support for this theory was provided by the finding that 
retrograde menstruation occurs in 90% of menstruating women [12]. Furthermore, forced surgical 
induction of retrograde menstruation in primate models leads to the development of endometriosis 
in 50% of cases [13]. However, there are drawbacks to Sampson’s theory. For example, retrograde 
menstruation cannot account for the occurrence of endometriosis in extra pelvic locations [14].  
Additionally, endometriosis is estimated to affect 1 in 10 women of reproductive age, equating to 
2.2 million sufferers in the U.K alone. Yet, the occurrence of retrograde menstruation is near 
universal, therefore the question remains as to why only a fraction of the population develops 
endometriosis? 
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A further confounding issue for the retrograde menstruation theory is the observation of 
endometriotic implants in men undergoing estrogen therapy for prostate cancer to consider [15-18]. 
It is well documented that the main trophic factor in endometriosis is estrogen [19], therefore it may 
well be possible that estrogen exposure plays a significant role in development of the disease. 
 
 
Illustrating endometrial cells travelling through the 
fallopian tubes onto the surface of the pelvic organs 
where they implant and proliferate (1). Here they form 
endometriotic implant of varying severity (2) which 
contain glands and stroma normally found in the eutopic 
endometrium (3).  
Figure 1. Retrograde Menstruation 
The left hand image shows normal endometrium with glands and stroma the dominant cell types. In 
the right hand image similar endometrial glands and stroma can be observed (arrows) only these are 
embedded deep into the wall of the bowel, illustrating a classic case of colonic endometriosis.  
Figure 2. Histology of Endometriosis 
 (Images courtesy of Dan Martin; The Fertility Institute 
of the mid-South, 2000-2007. AstraZeneca, 2008 and 
Cornell University Medical College, 1995.  
Images courtesy of Wolters-Kluwer, 2009 and University of Utah, Health Sciences Centre, 1993-2009 
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1.1.2 Coelomic Metaplasia 
In response to the limitations of retrograde menstruation, Gruenwald proposed in 1942 [20], that 
mesothelial cells of any organ, including those of the pelvic cavity, in particular the ovary, could 
undergo differentiation into functional endometrium; this came to be known as the theory of 
coelomic metaplasia and has since gathered support from several authors [21-24]. The process by 
which cellular differentiation into functional endometrium occurs remains speculative. It may be 
that steroid hormones or exogenous compounds induce the differentiation of normal mesothelial 
cells into endometriotic cells. Validation of this theory rests on its ability to explain how amenorrheic 
women and men undergoing hormone therapy occasionally present with endometriosis [15]. 
Additional support for this theory is the prediction that endometriosis may be found anywhere 
where mesothelium is present. Findings of endometriosis in the pleural cavity [25], diaphragm [26], 
brain [27] and several other organs [28-30] therefore adds credibility to the theory of coelomic 
metaplasia. However, it must be noted that metastasis of endometrial cells through the circulatory 
or lymphatic system may also account for the presence of endometriosis at these extra-pelvic sites 
[31].  
1.1.3 Immune System Abnormalities 
It has long been recognised that patients with endometriosis display alterations in the immunologic 
response. It is thought that defective immunosurveillance [32] may decrease the clearance of any 
refluxed menstrual debris, allowing the persistence of ectopic endometrial cells within the pelvic 
cavity.  Additionally, it is also thought that the observed abnormal immune response could promote 
the persistence and growth of ectopic endometrial cells [32, 33]. In the peritoneal fluid (PF) of 
women with endometriosis an increased concentration of macrophages has been reported [34]. 
Macrophages are involved in recognising foreign and damaged cells in the peritoneal cavity, once 
recognised these cells are then processed by macrophages for presentation to T lymphocytes. 
However, in patients with endometriosis malfunction of the peritoneal macrophages (PM) induces 
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them to secrete growth factors and cytokines that may promote the survival of ectopic endometrial 
cells. Similarly an alteration of the production of cytokines from T helper lymphocytes may induce 
changes in the consistency of the PF allowing a favourable environment for ectopic endometrial 
tissue proliferation. The regulation and activation of macrophages and lymphocytes is dependent on 
a fine balance of cytokine expression a balance that is upset in endometriosis [35]. A summary of the 
cytokines and growth factors thought to be involved in the pathogenesis of endometriosis is shown 
in Table 1.  
 
Factor Secreted from Function 
IL-1 PM, ESC May promote the survival of endometriotic cells by 
altering secretion of other cytokines such as IL-6, IL-8 and 
TNF-α [36, 37]  
IL-6 PM, ESC Promotes differentiation of macrophages and secretion 
of other cytokines 
IL-8 PM A potent angiogenic agent, thought to promote the 
neovascularisation of endometriotic implants [38] 
TNF-α PM Levels of TNF-α correlate strongly with disease stage [39]. 
May promote adherence of ectopic cells [40] 
IL-4 Th2 Inhibits production of IL-1, IL-6 and TNF-α. Stimulates 
production of IL-8 [41] 
IL-10 Th2 Involved in suppressing the immune response [42] 
TGF-β PM May act as a mitotic agent for ectopic endometrial cells 
[43] 
RANTES ESC Involved in recruiting leukocytes [32] 
IFN-γ Th1 Thought to be embryotoxic, activates macrophages [44]  
  
 
Table 1 is by no means a definitive list of all the immune system factors involved in endometriosis, 
rather it is a shortlist of the key components. The altered activity of these key components, many of 
which are involved in the inflammation response, also illustrates why endometriosis is considered a 
chronic inflammatory disease. The activation of inflammatory pathways is also a possible cause for 
Table 1. Immunologic factors involved in the pathogenesis of endometriosis 
IL = Interleukin, TNF-α = Tumour Necrosis Factor α, TGF-β = Transforming Growth Factor β, RANTES = Regulated upon 
Activation Normal T cell Expressed and Secreted, IFN-γ = Interferon-γ, PM = Peritoneal Macrophage, ESC = Endometrial 
Stromal Cell, Th1 = T-helper 1 cell, Th2 = T-helper 2 cell. 
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the pain associated with endometriosis [45].   However, it is not just over activity of the immune 
system that contributes to the pathogenesis of endometriosis. Decreased activity of natural killer 
(NK) cells has also been implicated in the pathogenesis of endometriosis [46, 47]. 
 
NK cells are responsible for clearing tumour cells, foreign cells and virus infected cells from the body 
and are activated by cytokines such as IL1, IL-2, IL-12, IFN-γ and TNF-a [48, 49]. Thus, it would be 
expected that NK cell activity should be up regulated in patients with endometriosis, however 
extensive experimental data shows that this is not the case [46, 47, 50, 51]. There have been several 
attempts to reconcile this paradox. It has been suggested that stimulation of antibodies by the 
presence of ectopic endometrium could lead to the formation of complexes that bind to Fc 
receptors present on the surface of NK cells that inhibit their function. Additionally, the production 
of prostaglandin E (PGE2) by activated macrophages may suppress NK activity [49, 52].  
1.1.4 The Genetics of Endometriosis 
Endometriosis is recognised as a heritable disease due to the finding that endometriosis is 
significantly more common in first degree relatives of women with the disease [53-55]. Additionally, 
a study of monozygotic twins reported that endometriosis was concurrent in 14 out of 16 twin sets 
[56], with further twin studies confirming the likelihood of endometriosis arising more frequently in 
close relatives [57, 58]. The heritable nature of endometriosis has prompted many to investigate 
which gene or sets of genes are responsible for the disease. To date many deregulated genes have 
been identified in endometriotic cells [59-62] with a wide variety of functions including apoptosis, 
cell cycle regulation, vascularisation, immune system regulation and cell adhesion. However, 
identifying the exact gene/s responsible has thus far failed. Some authors have linked certain genetic 
polymorphisms to endometriosis [63], however efforts to identify genetic polymorphisms consistent 
across cultural and ethnic backgrounds have also failed [63]. A multi-centre study between England 
and Australia which examined any regions of chromosomal linkage in sister paired endometriosis 
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sufferers has however narrowed down the region of interest. The results of this study identified that 
chromosome region 10q26 is significantly associated with endometriosis [64] and more recent 
studies have indicated region 7p15.2 is significantly associated with endometriosis [65], however no 
individual genes have been identified that may explain the heritable nature of endometriosis.  
 
More modern thinking has led to implications for the relatively new field of epigenetics in the origin 
and development of endometriosis. Epigenetics concerns heritable changes to gene expression that 
can be influenced by environmental factors but are not the result of changes to the DNA code. 
Examples of epigenetic mechanisms include; DNA methylation, loss of imprinting and gene 
regulation by microRNAs. Epigenetics has revolutionised the understanding of other complex 
multifactoral diseases such as cancer [66-68]. Recently it has emerged that epigenetic mechanisms 
likely play a significant role in the origin and progression of endometriosis [69]. Therefore, the 
application of an understanding of epigenetic mechanisms to the pathophysiology of endometriosis 
may lead to a better understanding of the origin and aetiology of the disease. Further discussion of 
epigenetics and its role in endometriosis is provided in Chapter 3. 
1.1.5 Environmental/Lifestyle Factors and Endometriosis 
Epidemiological data regarding endometriosis is currently limited. The few studies that have been 
undertaken suggest that lifestyle and dietary factors may be associated with susceptibility to 
developing endometriosis [70-72]. The results of these epidemiological studies found that a diet high 
in fruit and vegetables and low in meat products was protective against developing endometriosis. 
Additionally, women with few or no children and low body mass index (BMI) were at a higher risk of 
developing endometriosis. A summary of the lifestyle and environmental factors thought to be 
involved in the susceptibility to endometriosis are summarised on Table 2.   
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Risk Factor Increase/Decrease Risk 
Meat Consumption ↑ 
Alcohol Consumption ↑ 
Low BMI ↑ 
Fruit and Vegetable Consumption ↓ 
Parity ↓ 
Smoking ↓ 
 
Other authors have suggested that exposure to synthetic compounds such as dioxin and other 
polychlorinated biphenyls (PCBs) could lead to the development of endometriosis due to their 
effects as endocrine disruptors [73, 74]. Dioxin is a by product of the chlorine bleaching process used 
in the wood pulp processing industry, this also includes the manufacture of tampons which is 
thought to be a major source of dioxin exposure in women. However, the associations with dioxin 
are mainly based on animal data [75-77] which some authors criticise for poor study design and data 
analysis [78]. Human data on dioxin exposure and endometriosis risk is scant and in some cases 
appear contradictory. For example, a study reported that the incidence of deeply infiltrating 
endometriosis in Belgium, reportedly the highest in the world, correlates with high dioxin exposure 
through breast milk [79]. However, another study assessed massive dioxin exposure from the Seveso 
incident in Italy during the summer of 1976, whereby a chemical manufacturing plant accidentally 
released 1Kg of dioxin into the atmosphere, showering the neighbouring residential areas with 
dioxin. Although extremely high levels of dioxin contamination were found in soil and water 
samples, no significant increase in endometriosis incidence were observed, even after a 26 year 
follow up study [80]. Despite reported increased serum dioxin levels [81, 82], and increased serum 
levels of bisphenols [83] observed in endometriosis patients, a conclusive association between 
environmental toxicant exposure and increased risk of developing endometriosis has yet to be 
established.  
Table 2. Environmental and lifestyle factors associated with endometriosis 
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Given the variety and conflicting notions pertaining to the origin and development of endometriosis, 
it becomes clear why endometriosis is often referred to as the ‘disease of theories’. 
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1.2 The Structure and Function of the Endometrium 
 
Endometriotic cells are thought to be derived from the normal endometrium, therefore an 
understanding of the normal function of the endometrium is essential for the understanding of 
endometriosis [84]. The primary functions of the endometrium are to allow the implantation of the 
blastocyst and provide mechanisms for the clearance of tissue and haemostasis at menstruation. In 
order to achieve this the endometrium undergoes dramatic changes in structure and function during 
each menstrual cycle, which is classified into four distinct phases: menstrual, proliferative, ovulatory 
and secretory (Figure 3). It is normally stated that the menstrual cycle lasts 28 days, however it can 
vary from 20 to 34 days. The structural and functional changes that occur during each phase are the 
result of changes in the molecular components of the cells within the endometrium and are under 
the control of ovarian (estrogen and progesterone) and pituitary (Follicle stimulating Hormone and 
Luteinising Hormone) hormones.  The function of the endometrium is sensitive and tightly 
controlled, therefore abnormal or inappropriate cyclic changes are thought to be responsible for 
many common disorders of the female reproductive system, including abnormal uterine bleeding, 
infertility, endometriosis, adenomyosis and endometrial cancer [85].  
 
The Menstrual Cycle
Menstrual Phase 
(days 1-7)
Proliferatory Phase 
(days 7-13)
Ovulatory Phase 
(days 13-16)
Secretory Phase 
(days 16-28)
Figure 3. The menstrual cycle.  Adapted from; Endometriosis in Clinical Practice, by David Olive (2005) Taylor and Francis 
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The endometrium is composed of multiple cell types that form two distinct layers, the stratum 
basalis (which forms a constant basal layer for endometrial regeneration) and the stratum 
functionalis (which forms the section of the endometrium that proliferates and is shed during the 
menstrual cycle). The stratum functionalis is further divided into its various cell types, the stroma, 
glandular and luminal epithelium (Figure 4).  
 
 
 
 
 
 
 
Estrogen
Progesterone
LH
FSH
Menses Ovulation 
Luminal epithelium 
Glandular epithelium 
Stroma 
 
Figure 4. The structure of the endometrium during the menstrual cycle  
Showing the structure of the endometrium over the menstrual cycle and a micrograph image of the cellular 
components of the stratum functionalis. The glandular epithelium are a secretory gland, producing factors 
important for embryonic implantation. Adapted from; Endometriosis in Clinical Practice, by David Olive 
(2005) Taylor and Francis. Image courtesy of Current Medical Group, 2009.  
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Day one is often the onset of menses, and the proliferatory phase that follows is characterised by re-
epithelialisation occurring as early as day 2 [86]. By days 5-7 the endometrial epithelium covers the 
surface of the endometrium. A rise in estrogen levels over days 8-14 results in increased epithelial 
and stromal mitosis as well as proliferation of the glands. Constantly high levels of estrogen result in 
a surge of luteinising hormone (LH) which triggers ovulation about 34-36 hours after the LH surge. 
The resulting oocyte originates from an ovarian follicle which progresses to become a corpus luteum 
initiating the secretion of progesterone and estrogen. This signals endometrial transformation to the 
secretory phase. During the early secretory phase (days 15-18) progesterone levels are low and 
endometrial mitosis continues. During days 18-23 progesterone levels steadily rise and the 
endometrial glands secrete increased levels of pro-implantation factors (such as uteroglobin, 
trophinin and VEGF) into the lumen and arterioles also become spiral in appearance. If embryo 
implantation does not occur during the ‘window of implantation’ which is defined as days 20-24 
then the late secretory phase ensues from days 24-28. During this phase falling levels of estrogen 
and progesterone produce marked changes in tissue structure. Stromal decidualisation occurs along 
with regression of glandular epithelium and by day 27 specialised uterine leukocytes infiltrate. 
Finally, focal necrosis and haemorrhage are observed on day 28, predisposing the onset of menstrual 
bleeding.  
 
The endometrium also expresses a number of cytokines, essential for host immunity, correct cyclic 
timing, maintenance of pregnancy, and adhesion molecules, all requisite for successful implantation 
of the developing embryo [84].  
 
Since ectopic endometrial tissue is considered to be derived from eutopic endometrium, it is 
reasonable to suggest that ectopic endometrial tissue responds to changes in hormonal levels in the 
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same way as eutopic endometrium i.e. periodic growth and shedding. As ectopic endometrial 
implants are located within body cavities the resultant cellular debris has no means of escape 
thereby accumulating within the cavity leading to internal scarring and localised chronic 
inflammatory responses at the site of the endometriotic implant.  
1.2.1 Histology and classification of endometriosis 
Endometriosis can only be definitively diagnosed via laparoscopic visualisation of the endometriotic 
implants. Although this is a costly and invasive procedure that carries the inherent morbidity risk of 
any surgery, it does allow immediate surgical intervention at diagnosis, if necessary. However, 
endometriosis has a wide array of appearances, meaning laparoscopy can often give false positives 
or negatives. Endometriotic implants can be microscopic, penetrate deeply into tissue or have a 
subtle appearance making them almost impossible to observe with the naked eye [87]. Efforts to 
develop a non-invasive test for endometriosis have met with some success. Measurement of serum 
levels of the cell surface antigen CA-125, a tumour marker for ovarian cancer, have shown that 
women with moderate to severe endometriosis have increased levels of CA-125, indicating a shared 
pathological characteristics between endometriosis and ovarian cancer. However, women with 
minimal or mild endometriosis do not have significantly different CA-125 levels than controls [88]. 
This is problematic as severity of disease is often unrelated to the severity of symptoms [89]. In fact 
it has been reported that stage of endometriosis is indirectly proportional to severity of symptoms, 
with women with minimal endometriosis often suffering the most severe pain symptoms [90]. 
Further research into proteomics found certain urinary biomarkers, such as cytokeratin-19, were 
notably elevated in endometriosis [91] giving further hope for a future non-invasive test.  Therefore, 
unfortunately, there is no accurate non-invasive diagnostic test for endometriosis at present, thus 
diagnosis remains dependant on the visual appearance of endometriosis.  
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A typical endometriotic implant appears as a reddish-blue/black ‘powder burn’ lesion (Figure 5A), 
which owes its colouration to the amount of intraluminal haemosiderin and debris present [92]. A 
white appearance (Figure 5B) indicates a quiescent endometriotic lesion that is often difficult to 
distinguish between other implant types. Red endometriotic implants (Figure 5C) represent active, 
haemorrhagic implants with a dense vascular supply. Endometriotic implants behave much in the 
same way as normal endometrium in that they proliferate and haemorrhage in line with (but 
sometimes independently of) the menstrual cycle. This regular proliferation and haemorrhage leads 
to the formation of scar tissue and adhesions between pelvic organs (Figure 5D) that is thought to 
contribute significantly to the debilitating pain symptoms of endometriosis [93, 94].  
 
 
 
 
 
 
 
 
 
 
 
Endometriosis is also classified into different stages and grades [95]. The four stages of 
endometriosis are minimal, mild, moderate and severe. The staging system was devised by the 
Figure 5. The various appearances of endometriosis and adhesions at laparoscopy   
Images courtesy of www.endo-resolved.com, 2003-2009 and Wolters-Kluwer, 2009 
A B 
C D 
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American Fertility Society (AFS) which has undergone considerable updates since its inception in the 
1970s. The current AFS criteria for endometriosis staging, last revised in 1996, is based on a points 
system. Points are assigned for the severity of endometriosis based on the size and depth of the 
implant and the severity of adhesions.  For example 1-5 points = stage I – minimal, 6-15 points = 
stage II – mild, 16-40 points = stage III – moderate, 40 + points = stage IV – severe. Figure 6 shows a 
reproduction of the classification of endometriosis from the “Atlas of Laparoscopic and 
Hysterectomy Techniques” by W.B.Saunders [96].  
 
 
Figure 6.  AFS staging criteria for endometriosis 
 
Image reproduced from; Atlas of Laparoscopic and Hysterectomy Techniques, by W.B Saunders 
(1999) London Press  
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The American Society for Reproductive Medicine (ASRM) devised a grading system based on the 
appearance of endometriosis at laparoscopy.  This is divided into four grades depending on the 
extent of endometriotic tissue present and are outlined in Table 3 below. The AFS criteria carries 
several advantages over the ASRM method, such as more detailed description of location and type 
of endometriotic lesion.  
 
Grade Description 
Grade 1 Possible Endometriosis – Peritoneal vesicles, red polyps, yellow polyps, 
hypervascularity, scar, adhesions. 
Grade 2 Suggestive of endometriosis – Chocolate cysts with free flow of chocolate fluid. 
Chocolate cysts are endometriotic cysts filled with blood that has become 
brown with age. 
Grade 3 Consistent with endometriosis – Dark scarred (puckered pigmented or mixed 
colour) lesions, red lesion on fibrous scarred background, chocolate cyst with 
mottled red and dark areas on white background. 
Grade 4 Endometriosis – Dark, scarred (or puckered or pigmented) lesions at first surgery 
 
Endometriosis can also be diagnosed histologically. At surgery a suspected area of endometriosis can 
be excised and examined microscopically for signs of endometriosis. The presence of endometrial 
glands and stroma infiltrating any tissue type is classified as endometriosis. Figure 7 Illustrates a 
classic example of histological endometriosis. 
 
 
Normal tissue 
Endometrial stroma Endometrial glands 
Figure 7.  Microscopic view of endometriosis  
Table 3. Staging of endometriosis 
Normal tissue i.e. epithelium of the uterus, is shown at the top of the image. An 
endometrial gland embedded in the uterine tissue is characteristic of endometriosis. 
Stromal tissue surrounds the outer border of the glandular tissue.  Image courtesy of 
Current Medical Group, 2009 
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1.3 Current Medical Therapies for Endometriosis 
 
Therapies for endometriosis are divided into two types of treatment, pharmacological therapies aim 
to inhibit growth of the endometriotic implants, whereas surgical therapies aim to remove or 
destroy the endometriotic implants [6]. 
1.3.1 Medical Therapies for Endometriosis 
Endometriosis is an estrogen dependant disorder [97, 98], therefore current medical therapies are 
centred upon reducing circulating estrogen levels. This is usually achieved by down regulating 
ovarian production of steroid hormones (i.e. estradiol). Danazol, an isoxazol derivative of 17α-ethinyl 
testosterone (Figure 8) was the first drug to be approved for the treatment of endometriosis in the 
US [11]. Its anti-steroidogenic activity is known to relieve some of the symptoms associated with 
endometriosis [99], however substantial androgenic side effects, such as hair growth, mood changes 
and more seriously, liver damage and arterial thrombosis have been reported [100, 101]. 
 
 
1.3.1.1. Progestogens 
The anti-estrogenic effects of progesterone have been mimicked in an effort to create medical 
therapies for endometriosis [6].  These compounds, known as progestogens, include 
Medroxyprogesterone and Norethindrone (Figure 9), which are derivatives of progesterone and 19-
nortestosterone respectively. The drugs induce a pseudopregnancy state in which endogenous 
estrogen production is lowered. The mode of action of these drugs is thought to be due to their 
N
O
OH
CH
Figure 8. The structure of Danazol 
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suppression of the estrogen receptors, leading to endometrial decidualisation and eventual atrophy 
[102]. Additionally, these compounds have been shown to decrease the expression of matrix 
metalloproteinases, enzymes thought to be essential for the implantation and growth of ectopic 
endometrial cells [103]. Although these drugs are better tolerated than Danazol, their use still 
produces numerous side effects [104].  
 
 
1.3.1.2. GnRH Analogues  
Gonadotrophin-releasing hormone (GnRH) agonists are analogs of the hypothalamic hormone GnRH. 
GnRH is responsible for the normal function of the ovaries by stimulating the release of follicle 
stimulating hormone (FSH) and luteneising hormone (LH) from the pituitary gland. GnRH agonists 
bind to pituitary receptors resulting in a shutdown of pituitary hormone secretion which in turn 
down regulates the ovarian production of estrogen, thus creating a hypoestrogenic state much like 
that which the body undergoes during menopause. Starving the endometriotic cells of estrogen in 
CH3
O
O O
OH
O
OH
O
O
OH
CH
CH3
Progesterone 
Medroxyprogesterone 
19-nortestosterone 
Norethindrone 
Figure 9. Progestogens Medroxyprogesterone and Norethindrone shown as derivatives of their conjugate 
steroid hormones Progesterone and 19-nortestosterone 
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combination with alterations of plasminogen activators and matrix metalloproteinases [105] is 
thought to result in endometriotic atrophy. However, endometriotic cells are known to express the 
aromatase enzyme [106], ensuring their survival independent of ovarian steroids.  
 
GnRH agonist therapy is also associated with the side effects normally presented during menopause, 
such as hot flashes and loss of bone density, therefore in some cases small amounts of steroid 
hormone are administered in what is known as ‘add back’ therapy which appears to stem the 
severity of side effects without significantly affecting the relief of endometriosis associated pain 
[107].  
1.3.1.3. Combined Oral Contraceptive 
The combined oral contraceptive (COC) pill is commonly prescribed to women with endometriosis 
[108]. It consists of a combination of ethinyl estradiol and a progestin and induces a 
‘pseudopregnancy’ state. Although data regarding the mode of action of COCs is sparse, initial 
investigation suggests they suppress proliferation and induce apoptosis of endometrial cells [109].  
1.3.1.4. Aromatase Inhibitors 
The reported ineffectiveness of hormonal therapy may be due to the resistant nature of 
endometriotic cells to progestogenic compounds. The under-expression of progesterone receptors 
[110] and the over-expression of estrogen receptors [111, 112] in endometriotic cells would render 
them less sensitive to current progestogenic therapies [113]. In some instances the aromatase 
enzyme may be activated in endometriotic cells [114], cells expressing this enzyme can produce their 
own estrogen supply, independent of ovarian steroids.  Aromatase inhibiting compounds are 
currently being trialled for the treatment of endometriosis that is unresponsive to current therapy 
and have shown promising preliminary results [115].  
 
 21 
 
Despite the success rates of various treatments for endometriosis, their use if often associated with 
numerous side effects and can only suppress ectopic endometrial cells [108]. Thus, discontinuation 
of treatment would likely lead to recurrence of disease symptoms. This assumption is supported by 
studies which identified that resurgence of endometriosis is common after treatment is halted [116]. 
A survey of 7,025 endometriosis patients by the Endometriosis All Parliamentary Group comprising 
women from 52 different countries found that hormonal therapies such as those mentioned above 
were only 37% effective at relieving symptoms [117]. However, the degree of effectiveness varied 
between different types of therapy. Interestingly, 39% of respondents found that hormonal therapy 
decreased their quality of life scores.  It is also reported that 9% of women undergoing such therapy 
are completely unresponsive [118]. The side effects are unsurprising considering that most 
treatments have a whole body effect, not only affecting the ovaries, but also the brain and other cell 
types.  
 
The reported over-expression of aromatase in endometriotic cells highlights how endometriotic cells 
appear so resilient and self sustaining. Aromatase expression is also found to be increased in certain 
cancerous cell types [119], in particular breast cancer [119, 120]. Aromatase inhibiting drugs such as 
letrozole and anastrozole are established therapies for breast cancer [121] and these drugs are 
currently undergoing clinical trial as a possible therapy for endometriosis, with some encouraging 
results [122-124]. However, the use of aromatase inhibitors is associated with the side effects of 
creating a dramatically hypoestrogenic environment, such as bone density loss [125].  
1.3.1.5. Future Therapies 
Due to the relatively poor efficacy of hormonal therapy for endometriosis, several other 
experimental therapies are currently undergoing clinical trial, such as Mifepristone (a selective 
progesterone receptor modulator) [126] and Dienogest (a progestin) [127]. Aromatase inhibitors 
have almost graduated from the pantheon of potential future therapies for endometriosis, since 
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they are now considered an acceptable therapy for endometriosis that does not respond to 
conventional treatments. However, there are other, novel medical therapies designed to exploit 
characteristics of endometriotic cells as potential drug targets. One such therapy is anti-angiogenic 
therapy [128]. Endometriotic tissue is thought to be derived from that of normal endometrium, 
which is a highly vascular tissue and one of the only such tissues in the adult human body that 
regularly undergoes the formation of new blood vessels. Support for this hypothesis comes from the 
observation that endometriotic implants are well supplied by vascular structures [129]. Animal 
models have also shown that endometriotic implants need an adequate angiogenic response in 
order to successfully survive [129, 130]. Several angiogenic factors, including the potent and well 
studied angiogenic factor vascular endothelial growth factor (VEGF), have been reported to be up 
regulated in endometriotic implants [131], endometrioma [132] and in the PF of women with 
endometriosis [133, 134]. Drugs that inhibit the formation of new blood vessels via a variety of 
mechanisms such as TNP-470, endostatin, VEGF-A blocking antibodies, methoxyestradiol and 
anginex, have all shown potential as anti-angiogenic therapies for endometriosis in animal models 
[135-139].  However, some drawbacks to this approach include the reduction in fertility observed in 
animals and patients taking anti-angiogenic therapy for cancer [140] and the possibility that not all 
the endometriotic tissue would be regressed by a single anti-angiogenic therapy owing to the 
heterogeneous nature of diseased tissue [135].   
 
Recently Hassan et al [141] have suggested that gene therapy may be a novel approach to 
endometriosis treatment. Gene therapy involves delivering genetic material to diseased cells via a 
suitable vector in order to correct aberrant gene expression observed in disease cells. A study in 
2002 by Dabrosin et al [142] used adenovirus vectors to deliver genes encoding the angiogenesis 
inhibitor, angiostatin, into mice engineered to develop endometriosis. This study reported 100% 
eradication of endometriotic implants in mice receiving the adenovirus compared to 15% reduction 
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observed in the control group. However, this study also reported a decrease in the indicators of 
fertility in adenovirus treated mice. Another approach suggested by Hassan et al [141] was to use 
adenovirus vectors to deliver dominant negative mutants of the estrogen receptor (DNER) to 
endometriotic cells. This would greatly reduce the sensitivity of endometriotic cells to estrogen and 
thus, atrophy their growth. Early results from this therapy have been encouraging, indicating 
increased cell death in endometriotic cells [143]. Such a treatment regime would confer advantages 
to the patient. For example, current hormonal therapy for endometriosis acts upon the whole body, 
often leading to many side effects. Gene therapy may also allow targeted therapeutics to specific cell 
types [144] and act at the cellular level greatly reducing unwanted side effects. Gene therapy 
however, is still in its infancy and suffers certain drawbacks such as rejection of the viral vectors by 
the host, short half life of the therapeutic DNA, and as only one gene can be corrected at a time, at 
present it is unsuitable for multifactoral diseases like endometriosis.  
1.3.2 Surgical Therapy for Endometriosis 
If medical therapy proves unsuccessful or the stage of endometriosis is considered too advanced 
then surgical intervention is often the only remaining option [6]. However, appropriate treatment 
varies significantly depending on the woman’s age, parity and the nature of the symptoms. Surgery 
falls into two main categories, conservative surgery which can usually be performed via laparoscopy 
and radical surgery which normally involves the partial or entire removal of the affected organ.  
1.3.2.1. Surgical Excision/Ablation of Endometriosis 
The degree to which endometriotic implants cause pain is strongly related to the nature of the 
implant. It has been reported that deeply infiltrated endometriotic implants are most commonly 
associated with pain. Superficial implants on the other hand are often associated with minimal 
symptoms [145]. Excision of the endometriotic implant can be performed using a variety of 
techniques but all involve the cutting away of endometriotic tissue from healthy tissue. There are 
few well designed studies to assess the success of excisional therapy for the treatment of 
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endometriosis associated symptoms therefore it is hard to assess the benefits of this procedure over 
others. Additionally, complete excision of an endometriotic implant can be difficult. Koninckx et al 
[146] reported that despite an aggressive surgical approach, total removal of the implant could not 
be achieved more that 90% of the time [146], and even then complete removal of the implant was 
associated with serious complication in a quarter of cases. 
 
Some surgeons forgo the use of excisional therapy in favour of ablative destruction of the 
endometriotic implant. This can be performed via a variety of techniques such as electrocautery or 
laser vaporisation. There are a number of reports on the use of ablation for managing the symptoms 
of endometriosis [147-149]. The overall conclusions that can be drawn from these studies indicate 
that surgical ablation has around a 60% success rate after 2 years (that is 60% of patients were pain 
free after 2 years). However, pain and individual’s response to pain differs, affecting the conclusion 
that can be drawn from these studies.  
1.3.2.2. Radical Surgery for Endometriosis 
If management of endometriosis is not achievable by medical and minor surgical intervention, 
radical surgical options may have to be explored. Often this will involve the partial or complete 
removal of the affected organ. Most common procedures include hysterectomy (removal of the 
uterus) and oopherectomy (removal of the ovaries), although removal of the ovaries would require 
premenopausal patients to undergo hormone replacement therapy to lessen symptoms of estrogen 
deprivation. A seven year follow up study of 240 women who underwent surgery reported the 
following findings summarised in Table 4 on the effect of various surgical procedures for the relief of 
endometriosis associated pain based on the need for further surgery [150].  
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 Excision only Hysterectomy only Hysterectomy and oopherectomy After 2 years 30.6% 4.3% 4% After 5 years 46.7% 13.4% 8.3% After 7 years 65.4% 23% 8.3% 
 
Therefore, conclusions can be drawn from the result of this study. Firstly it would appear that 
surgical excision alone frequently requires further surgery suggesting a high rate of disease 
recurrence. Total hysterectomy with oopherectomy was the most successful surgery long term. This 
is most likely due to removing the source of potential refluxed endometrium (the uterus) and the 
source of mitogenic steroid hormones (the ovaries). Therefore, this also gives support to the 
retrograde menstruation theory, as it would appear removing the anatomical features nessacary for 
retrograde menstruation drastically reduces the recurrence of endometriosis. However, this study 
did not address issues such as what medical therapy, if any, the patients selected for this study were 
taking post-operatively, a factor which may influence the recurrence of the disease.   
Table 4. Success of surgery related to endometriosis 
 
Numbers relate to percentage of women who required further surgery 
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Chapter 2. A Novel Model for Predicting the Prevalence of 
Endometriosis 
 
2.1. Background 
The exact prevalence of endometriosis in any one country is difficult to predict with any degree of 
accuracy due to the invasive and subjective diagnostic procedures required to diagnose 
endometriosis. Although non-invasive methods for detecting endometriosis are currently under 
development, such as the CA125 antigen test [151], ultrasound scanning [152] and endometrial 
nerve density [153], definitive diagnosis of endometriosis can only be achieved visually via 
laparoscopy. However, diagnosis is a subjective matter depending on the skill of the surgeon and the 
quality of equipment used. Therefore, in poorer countries prevalence rates of endometriosis may be 
under represented due to lack of specialised doctors and poor quality surgical equipment.  The 10% 
figure is often quoted as a universal constant for endometriosis prevalence. This may be erroneous 
however, given the heterogeneity of the world’s populations the prevalence of endometriosis is 
likely to vary widely. Like many other diseases, prevalence of endometriosis will vary throughout the 
world but without a simple, objective diagnostic method the true prevalence of endometriosis 
within certain populations cannot be accurately measured. Endometriosis is a multifactoral disease, 
meaning it is highly unlikely a singular causative factor will ever be found. Like certain cancer types 
lifetime endometriosis risk is influenced by a number of factors. However, from the few 
epidemiological studies that have assessed endometriosis, certain factors can be used as indicators 
for the likelihood of endometriosis arising in populations where those factors are known. For 
example, the epidemiological data on endometriosis suggests that women with high parity, low 
meat consumption, high fruit and vegetable consumption, low alcohol consumption and live in a 
rural environment are less likely to develop endometriosis than those who have low parity, high 
meat consumption etc [70, 71]. Additionally, women with endometriosis have been shown to have 
an increased risk of developing ovarian cancer [154]. The reason for this is thought to be due to 
 27 
 
endometriosis of the ovary representing a pre-malignant state in some cases [155, 156]. Whilst the 
prevalence of endometriosis in most of the world’s countries may not be known, data on the above 
mentioned risk factors is well documented for most countries.  
2.2. Aim 
The aim of this study is to create a novel method for predicting the prevalence of endometriosis in 
different countries based on known risk factor data. 
2.3. Methods 
2.3.1. Collection of risk factor data 
Data on the following risk factors for endometriosis was harvested for 165 countries:  
1) Parity (average children per woman according to World Health Organisation 2004 [157]). The 
WHO collects metadata on parity from records of births averaged by the number of the female 
populace according to the latest population statistics for that country. WHO data has been used in a 
number of published peer reviewed articles [158, 159] and is thus deemed reliable.  
2) Plant to animal matter consumption ratio (in calories per capita per day according to the Food and 
Agriculture Organisation metadata [160] 2001, calculated using the following equation,  
where Ap = mean consumption of total plant material for that country in calories per capita per day 
and Aa = mean consumption of total animal material for that country in calories per capita per day). 
Plant matter is defined as the total consumption of the following food types classified by the FAO: 
fruit, vegetables, cereals, nuts and seeds. Animal matter is defined as the total consumption of the 
following food types as classified by the FAO: red meat (beef, lamb), white meat (chicken) and fish. 
3) Alcohol consumption (in Kg per capita per year according to the Food and Agriculture 
Organisation [160] 2003). Alcohol is defined as the total consumption of the following alcohol types 
according to FAO classification: wine, beer and spirits. Consumption of plant matter, animal matter 
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and alcohol is calculated by the FAO by dividing consumption index by index of population. 
Metadata gathered by the FAO has been used in a number of peer reviewed articles [161, 162] and 
is therefore deemed reliable.  
4) Percentage of population in urban environment (according to the World Health Organisation 
[157] 2005). Urban environment is defined by the WHO as any area where the population exceed or 
is equal to 1,500 people per square kilometre.  
5) Incidence of ovarian cancer (incidence rates per 100,000 women according to Globocan 2002 
[163]) were used to estimate the incidence of endometriosis for all countries where the data on risk 
factors were available. Globoan is a database of the CANCERMondial website and is managed by the 
Cancer Information Section of the IARC (International Agency for Research on Cancer) in conjunction 
with the WHO. Cancer indices are gathered from international cancer registries. All statistics 
provided by Globocan are age-adjusted. 
The sum of these risk factor data that are used for predicting the prevalence of endometriosis is 
presented in Appendix 1.  
2.3.2. Prediction of Endometriosis 
The risk factor data (Appendix 1) were used to predict the prevalence of endometriosis around the 
world. Countries that did not have data for all risk factors were eliminated from the analysis as they 
would represent incomplete data to obtain the prediction. Of the 165 countries, 44 were eliminated 
from the analysis. The reason these countries were eliminated was due to insufficient or missing 
data on the risk factors chosen for the prediction model. Difficulty arises when attempting to 
compare the data for each risk factor as each risk factor is given in units of measurement that are 
incompatible with one another, therefore a rank scoring scale had to be been established that gives 
the level of each risk factor for a certain country a comparative rank score out of five. The five ranks 
have been termed ‘very low’, ‘low’, ‘medium’, ‘high’ and ‘very high’ and correspond to the data 
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percentiles used in figures 10-15. However, firstly the risk factors were divided into protective and 
suggestive risk factors. Protective risk factors will decrease the incidence of endometriosis the higher 
their levels are i.e. fertility and plant to animal matter consumption ratio. Therefore, the rank 
scoring system for protective risk factors will be as demonstrated below 
Rank Very Low Low Medium High Very High 
Score 5 4 3 2 1 
Percentile 0-20 20-40 40-60 60-80 80-100 
 
Conversely suggestive risk factors will increase the incidence of endometriosis the higher their levels 
are i.e. alcohol consumption, urban living and ovarian cancer incidence. Therefore, the rank scoring 
system for suggestive risk factors will be reversed, as demonstrated below. 
Rank Very Low Low Medium High Very High 
Score 1 2 3 4 5 
Percentile 0-20 20-40 40-60 60-80 80-100 
 
Each country then has its score calculated based on the relevant rank it falls into for each risk factor. 
This data is supplied in Appendix 3. The maximum achievable score is 25, therefore the total score 
for each country was divided by 25 in order to obtain a relative endometriosis risk index (ERI). The 
ERI therefore ranges from 0 to 1. The closer a country’s individual ERI is to 1 the higher predicted 
prevalence of endometriosis in that country. For example, an ERI of 0.95 would indicate that country 
has a high prevalence of endometriosis, conversely a score of 0.20 would indicate a low prevalence 
of endometriosis. The results of these data are presented in Figure 15. 
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2.3.3. Comparison of Age at Menarche and Human Development Index 
There are also additional risk factors that can be taken into consideration but have less data 
available. For example, age at which menses begin (menarche) is considered to be one of the most 
important risk factors for endometriosis. Women who reach menarche earlier are more likely to 
develop endometriosis than those who have a later menarche [164-167].  The limited studies that 
have analysed data on age of menarche throughout various countries found that developed 
countries had a lower average age of menarche (e.g. Britain, 13.3 [168], Australia, 13 [169], Japan, 
12.5 [170], USA, 12.8 [171] than developing countries (e.g. Somalia, 14.78 [172], Tanzania, 15.21 
[173], Nigeria, 15 [169], Bangladesh, 15.8 [174], India, 14.31 [175]. The data above does not 
unequivocally prove that developing countries have a lower age of menarche though, it merely infers 
this conclusion. In order to prove the hypothesis that age of menarche (and therefore risk of 
endometriosis) is related to developmental status of a country firstly an indicator of a country’s 
development status needs to be selected.  
 
The Human Development Index (HDI) is a numerical value compiled by the United Nations 
Development Program (UNDP) given to a country represented by a value between 0 and 1. The HDI 
of a country is calculated by comparing normalised factors such as life expectancy, literacy and 
education indices and standard of living indices for a given country and reflects that country’s 
development status. HDI data has been complied every 5 years since 1975. Age of menarche data 
has been compiled by Thomas et al and Morabia et al [169, 176]. Age at menarche data was date 
matched with HDI data for the closest year. Therefore, it is now possible to compare a country’s 
developmental status with age of menarche. According to literature searches there has been no 
analysis to date that has investigated the relationship between age at menarche and the 
developmental state of a country. Since the data on age at menarche was compiled over several 
years it has be matched with HDI data for the closest year, a full listing of the data is presented in 
Appendix 2. Analysis of this data yielded some interesting results, firstly age at menarche was 
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plotted against HDI score (Figure 16), then Spearman’s Rank correlation coefficient was calculated 
for the two data sets.  
 
Using the HDI score it is also possible to compare the developmental state of a country to the 
predicted ERI score in order to test the hypothesis that developmental index is related to risk of 
endometriosis. In order to test this hypothesis ERI was plotted vs HDI values for 2006 for the 120 
countries where both data was available. The results are plotted on Figure 17 and Spearman’s Rank 
correlation calculated.  
 
2.4. Results 
Analysis of the data shows some patterns in likely areas of endometriosis risk across the globe. In 
order to better visualise the tabulated data from Appendix 1 and Appendix 3 and judge patterns in 
risk, Figures 10-15 below represent a broad overview of the data obtained on maps of the world 
with colour coded levels of risk, a key is provided for each diagram explaining the risk levels. 
Countries where no data were available are represented as grey. 
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Risk Level Description 
Very low Represents the 0-20th percentile of data i.e. those women who, on average have 
less than 1 child  
Low Represents the average 21-40th percentile of data i.e. those women who, on 
average have between 1 - 2.9 children  
Medium Represents the average 41-60th percentile of data i.e. those women who, on 
average have between 3 – 4.9 children  
High Represents the average 61-80th percentile of data i.e. those women who, on 
average have between 5 – 6.9 children  
Very High Represents the average 81-100th percentile of data i.e. those women who, on 
average have over 7 children  
 
Worldwide the mean fertility rate is 2.9 ± 1.6 children per woman. Figure 10 shows fertility rates are 
highest in Central Africa, the Middle East and Southern Asia. Highest fertility rates were recorded in 
Niger (7.8 children per woman) and Uganda (7.1). Fertility rates are lowest in Europe, China and 
Canada. Lowest fertility rates were recorded in Ukraine (1.1). Figure 21 shows the relationship 
between predicted Endometriosis Risk Indices and fertility data.  
 
Figure 10. Risk Factor - Fertility 
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Risk Level Description 
Very low Represents the 0-20th percentile of data i.e. those populations who have a plant to 
animal consumption ratio of 0-2.9 
Low Represents the average 21-40th percentile of data i.e. those populations who have a 
plant to animal consumption ratio of 3-5.9 
Medium Represents the average 41-60th percentile of data i.e. those populations who have a 
plant to animal consumption ratio of 6-9.9 
High Represents the average 61-80th percentile of data i.e. those populations who have a 
plant to animal consumption ratio of 10-12.9 
Very High Represents the average 81-100th percentile of data i.e. those populations who have 
a plant to animal consumption ratio of 13-15+ 
 
 Worldwide the mean plant to animal matter consumption ratio was 8.3 ± 8.5. Figure 11 indicates 
plant matter constitutes a higher proportion of the diet of people in central Africa and North Korea. 
Highest levels of plant matter consumption were recorded in Democratic republic of Congo (ratio 
45.57) and Mozambique (42.84). Meat constitutes a greater proportion of the diet in Northern 
Europe, Australia, North and South America, the Middle East and South Africa. Highest meat 
consumption was recorded in Iceland (ratio 1.45) and Denmark (1.53). Figure 22 shows the 
relationship between predicted ERI scores and dietary plant to animal matter consumption ratios.  
Figure 11. Risk Factor – Plant to Animal Matter Consumption Ratio 
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Risk Level Description 
Very low Represents the 0-20th percentile of data i.e. those populations who have an average 
alcohol consumption of between 0 – 20.9 Kg/capita/year 
Low Represents the average 21-40th percentile of data i.e. those populations who have 
an average alcohol consumption of between 21 – 40.9 Kg/capita/year 
Medium Represents the average 41-60th percentile of data i.e. those populations who have 
an average alcohol consumption of between 41 – 60.9 Kg/capita/year 
High Represents the average 61-80th percentile of data i.e. those populations who have 
an average alcohol consumption of between 61 – 80.9 Kg/capita/year 
Very High Represents the average 81-100th percentile of data i.e. those populations who have 
an average alcohol consumption of between 81 – 100+ Kg/capita/year 
 
Worldwide the mean alcohol consumption is 46.7 Kg/capita/year ± 44.7. Figure 12 shows alcohol 
consumption is highest in Europe, North America, Australia and South Africa. Highest levels of 
alcohol consumption were recorded in Ireland (211 Kg/capita/year). Intermediate areas of alcohol 
consumption include South and Central America. The lowest level of alcohol consumption was 
recorded in Bangladesh, Indonesia, Iran, Kuwait, Myanmar, Niger, Pakistan, Saudi Arabia, Sudan and 
Yemen (0 Kg/capita/year). Figure 23 shows the relationship between predicted ERI scores and 
alcohol consumption data. 
Figure 12. Risk Factor – Alcohol Consumption 
 
 35 
 
 
Risk Level Description 
Very low Represents the 0-20th percentile of data i.e. those populations where on average 0-
20% of the populace live in an urban environment 
Low Represents the average 21-40th percentile of data i.e. those populations where on 
average 21-40% of the populace live in an urban environment 
Medium Represents the average 41-60th percentile of data i.e. those populations where on 
average 41-60% of the populace live in an urban environment 
High Represents the average 61-80th percentile of data i.e. those populations where on 
average 61-80% of the populace live in an urban environment 
Very High Represents the average 81-100th percentile of data i.e. those populations where on 
average 81-100% of the populace live in an urban environment 
 
Worldwide the mean percentage of people who live in urban environments is 57.3% ± 21.7. Figure 
13 shows the majority of the populace of North America, South America, Northern Europe and 
Australia live in urban environments. The highest % of urban population was found in Belgium 
(97.3%) and Kuwait (96.4%). Around half the population of China and Central Africa live in urban 
areas. The lowest rates of urban living are found in sub-equatorial Africa and Southern Asia. The 
lowest rates of urban population were found in Uganda (12.4%) and Ethiopia (16.2%). Figure 24 
shows the relationship between predicted ERI scores and percentage of population living in urban 
environments.  
Figure 13. Risk Factor – Urban Living 
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Risk Level Description 
Very low Represents the 0-20th percentile of data i.e. those populations where the average 
ovarian cancer incidence is between 0 – 2.9 cases per 100,000 women 
Low Represents the average 21-40th percentile of data i.e. those populations where the 
average ovarian cancer incidence is between 3 – 5.9 cases per 100,000 women 
Medium Represents the average 41-60th percentile of data i.e. those populations where the 
average ovarian cancer incidence is between 6 – 8.9 cases per 100,000 women 
High Represents the average 61-80th percentile of data i.e. those populations where the 
average ovarian cancer incidence is between 9 – 11.9 cases per 100,000 women 
Very High Represents the average 81-100th percentile of data i.e. those populations where the 
average ovarian cancer incidence is between 12 – 15+ cases per 100,000 women 
 
Worldwide the mean incidence of ovarian cancer is 7.4 cases per 100,000 ±3.7 (2002). Figure 14 
shows ovarian cancer incidence rates are high in North America, Southern and Eastern and Northern 
Europe. Highest incidences were reported in Iceland (17.0 cases per 100,000) and Lithuania (16.6 
cases per 100,000). Areas where ovarian cancer incidences are around the mean include South 
America and Australia. Lowest Ovarian cancer rates are found in Central and sub-equatorial Africa as 
well as South East Asia. The lowest incidence was reported in Egypt (1.0 cases per 100,000). Figure 
25 shows the relationship between predicted ERI scores and rates of ovarian cancer. 
Figure 14. Risk Factor – Ovarian Cancer 
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Figure 15 show the sum of predicted Endometriosis Risk Indices worldwide. It indicates 
endometriosis prevalence is highest in North America, Europe and Australia, being highest in 
Belgium, Germany, United Kingdom and New Zealand (ERI 0.96. Intermediate areas of predicted 
endometriosis risk include North Africa, South Asia and Central America. Lowest areas of predicted 
endometriosis risk occur around Central Africa, being lowest in Malawi (ERI 0.24). The mean ERI 
worldwide is 0.64 ± 0.20.  
  
Risk Level Description 
Very low Represents those countries with an Endometriosis Risk Index between 0.00 – 0.19 
Low Represents those countries with an  Endometriosis Risk Index  between 0.2 – 0.39 
Medium Represents those countries with an  Endometriosis Risk Index  between 0.4 – 0.59 
High Represents those countries with an  Endometriosis Risk Index  between 0.6 – 0.79 
Very High Represents those countries with an  Endometriosis Risk Index  between 0.8 - 1 
Figure 15. Predictive Endometriosis Prevalence  
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Figure 16 displays the correlation between HDI and Age at menarche for countries throughout the 
world with linear regression.  
 
 
Spearman Rank correlation = -0.6343 which is indicative of a weak negative relationship, however 
the critical P value for this result is <0.001 indicating that although this was a weak correlation it was 
highly statistically significant.  
Figure 17 displays the correlation between HDI and the predicted Endometriosis Risk Index (ERI) with 
linear regression.  
 
 
R² = 0.4461
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
11.00 12.00 13.00 14.00 15.00 16.00 17.00
H
D
I I
nd
ex
 (d
at
e 
ad
ju
st
ed
)
Age at Menarche (years)
R² = 0.799
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 0.2 0.4 0.6 0.8 1
H
D
I 2
00
6
Endometriosis Risk Index
Figure 16. Age at menarche vs Human Development Index 
Figure 17. Human Development Index vs Endometriosis Risk Index 
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Although the R2 value of 0.799 indicates a strong correlation, Spearman Rank correlation = 0.9133 
which is indicative of a very strong, statistically significant association. Therefore, age at menarche is 
associated strongly with risk of endometriosis and age at menarche is inversely related to HDI. 
 
 
 
Linear regression gives an R2 value of 0.3528 indicating a weak correlation between the predicted 
ERI values and Fertility rates. Spearman Rank correlation = -0.797 indicating a moderate negative 
correlation with critical P values <0.001 indicating it is statistically significant.  
 
 
Logarithmic regression gives an R2 value of 0.4841 indicating a weak correlation between the 
predicted ERI values and Plant: Animal matter consumption ratios. Spearman Rank correlation =         
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Figure 18. Endometriosis Risk Index vs Fertility  
Figure 19. Endometriosis Risk Index vs Plant:Animal matter ratio 
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-0.9121 indicating a strong negative correlation with critical P values <0.001 indicating it is 
statistically significant.  
 
 
 
Linear regression gives an R2 value of 0.2455 indicating a very weak correlation between the 
predicted ERI values and percentage population living in urban environments. Spearman Rank 
correlation = 0.7747 indicating a moderate positive correlation with critical P values <0.001 
indicating it is statistically significant.  
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Figure 21. Endometriosis Risk Index vs Alcohol consumption 
Figure 20. Endometriosis Risk Index vs Urban living 
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Linear regression gives an R2 value of 0.4139 indicating a weak correlation between the predicted 
ERI values and alcohol consumption. Spearman Rank correlation = 0.7481 indicating a moderate 
positive correlation with critical P values <0.001 indicating it is statistically significant.  
 
 
 
Linear regression gives an R2 value of 1.00 indicating a perfect correlation between the predicted ERI 
values and ovarian cancer incidence. Spearman Rank correlation = 0.8208 indicating a strong positive 
correlation with critical P values <0.001 indicating it is statistically significant.  
 
2.5. Discussion 
As the true prevalence of endometriosis throughout countries of the world is unknown, a prediction 
model such as the one outlined in this chapter is our best method of estimating endometriosis 
prevalence. This is the first study of its kind to attempt to provide a satisfactory endometriosis 
prediction model.  
 
Choosing the correct risk factors for this study is essential, yet this study has been limited to risk 
factors where data is well documented. Other risk factors have been suggested for increasing the 
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Figure 22. Endometriosis Risk Index vs Ovarian cancer incidence 
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incidence of endometriosis, such as light skin pigmentation [177, 178], menstrual characteristics [54, 
179] and specific pollutant exposure [75, 82] however, accurate data on such risk factors is either 
scant or non-existant. Each risk factor has been selected based on evidence linking each one to 
either a decrease or increase in risk of developing endometriosis.  
 
Figure 18 shows that there is a weak negative relationship between the predicted ERI score and 
number of children. Parity has long been recognised as a protective factor [166, 180]. The reason for 
this is thought to be due to the suppression of ovarian estrogen production during pregnancy, 
effectively starving any endometriotic lesions of their main trophic factor. Although pregnancy is 
often touted as a cure for endometriosis this is a fallacy, as endometriosis can recur postnatally. In 
point of fact a retrospective study of 345 women with endometriosis found that recurrence of 
disease symptoms was significantly increased after the birth of the first child [181].  
 
Figure 19 shows that there is a slightly more significant relationship between predicted ERI scores 
and plant: animal matter consumption ratio. Greater consumption of plant matter appears to be 
associated weakly with a lowered risk of endometriosis. Epidemiological data has suggested that diet 
plays a role in endometriosis susceptibility, specifically consumption of fruit and vegetables 
reportedly decreases risk whereas meat consumption, particularly red meat, increases risk [70, 71]. 
High plant matter consumption may be an indicator of a generally healthy lifestyle, thus lowering 
overall disease rates. However, studies indicate a diet high in fruit and vegetables is protective 
against endometrial cancer [182], fibroids [183] and epithelial ovarian tumours [184], all of which 
are thought to be associated with estrogen dependency and endometriosis [185-187]. The 
protective effect of plant matter may be due to higher concentrations of vitamin C, carotenoids, folic 
acid, micronutrients and phytoestrogens present in such foodstuffs, which may decrease cellular 
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proliferation [188, 189]. Animal matter, in particular animal fats, are thought to increase the 
production of prostaglandins and increase the production of circulating estrogens [190, 191]. 
Additionally, the heterocyclic amines, residual hormones and growth enhancers found in red meat 
are thought to act as estrogenic compounds [192, 193] which may increase the proliferation of 
endometriotic implants.  
Figure 20 shows that there is only a very weak association between predicted ERI scores and urban 
living. According to these results urban living is not associated with any significant increase in 
endometriosis risk. Living in urban environments has been suggested as a risk factor for 
endometriosis [164, 180], as it is thought that increased concentrations of endocrine disrupting 
chemicals (EDCs) present in pollution associated with dense urban areas may contribute to the 
development of endometriosis [73]. EDCs are chemicals that can interfere with normal hormonal 
signalling systems, either by blocking or modulating the synthesis, transport, binding and 
metabolism of endogenous hormones.  Dioxin and polychlorinated biphenyls (PCBs) are the EDCs 
mostly cited as involved in endometriosis risk due to estrogenic activity [75, 82], although the 
association between such EDCs and endometriosis is tenuous (see section 1.1.5).  Similarly, the EDC 
properties of phthalate esters have been associated with endometriosis in some studies [194, 195], 
but not others [196]. Phthalate esters are ubiquitous environmental pollutants known to be found in 
high concentrations in urban environments [197, 198]. The source of phthalate exposure is 
predominately plastic food containers but other sources include; plastic flooring (vinyl), 
pharmaceutical coatings and airborne dust. Further discussion on the transgenerational effects of 
EDCs is presented in section 3.1.5. Associations have also been made between endometriosis risk 
and lead pollution [199], which is known to be high (between 180-200ng/m3) in urbanised areas, 
mainly due to vehicle emissions [200-202].  
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Figure 21 shows that there is a weak association between predicted ERI scores and alcohol 
consumption. Alcohol consumption has been cited as a risk factor for endometriosis [72, 164, 165, 
203], although not all studies are concordant [204]. Those that show a correlation between 
endometriosis and alcohol only note alcohol consumption of the sufferer, which may not be a 
causative factor. Rather endometriosis may be a causative factor for increased alcohol consumption 
due to the analgesic effects of alcohol. Some of the above studies reported intrauterine exposure to 
alcohol did not result in any subsequent increase in endometriosis risk. However, this study was 
based on retrospective data recollection by the sufferer’s mothers that may hinder accurate data 
collection due to each sufferer being between the ages of 18-40. Additionally, inheritance of 
endometriosis from the mother was not controlled for. Alcohol is thought to increase the risk of 
endometriosis by increasing circulating estrogen levels [205] and increasing the expression of 
estrogen receptors [206]. Red wine has also been reported to increase the expression of aromatase 
in adipose tissue [207], which may further contribute to increased estrogen production. Due to the 
extensive, reliable data collected on alcohol consumption by the FAO it was included as a predictive 
risk factor for endometriosis for this study. 
  
Figure 22 shows a perfect correlation between predicted ERI scores and ovarian cancer incidence. 
This result is unusual because of its perfect correlation, one would expect that being as the ERI 
scores are derived from five separate factors, there would be no one factor with perfect correlation. 
Therefore, this result should be treated with caution and is most likely an artefact. Although it is 
considered a rare event, endometriosis of the ovary (endometrioma) has long been recognised as 
possessing the ability to transform into a malignant state, in particular epithelial and clear cell 
carcinoma [208]. Cancer is recognised as a stepwise accumulation of genetic lesions that eventually 
result in malignancy [209]. Endometrioma may be considered one of the intermediate steps 
between normal tissue and malignancy due to similar genetic risk factors associated with 
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endometriosis and cancer [210]. Therefore, although some variation is likely to exist, it is reasonable 
to conclude that countries which have a higher incidence of ovarian cancer would also have a higher 
incidence of endometriosis. Given the wealth of data on global ovarian cancer incidence collected by 
the WHO it is reasonable to have included it as a risk factor for this study. The relationship between 
endometriosis and cancer is discussed further in section 3.5. 
 
Countries with the highest ERI score (0.96) were Belgium, Denmark, Germany, New Zealand and 
United Kingdom. Countries that fell along the mean ERI value (0.64) were Armenia, Azerbaijan, 
Bolivia, Ecuador, Lebanon, Malaysia, Paraguay, Peru, Philippines and Turkmenistan. The country with 
the lowest ERI score (0.24) was Malawi preceded closely by Yemen, Mozambique and the 
Democratic Republic of the Congo with an ERI score of 0.28. Analysis of these data reveals obvious 
trends in patterns of endometriosis risk. For instance, countries across the equator, in particular 
central Africa appear likely to have low prevalence’s of endometriosis (i.e. likely much lower than 
the standard 10% prevalence rate) due to consistently high protective factors and low suggestive 
factors. The converse can be said for developed countries such as those in North America and 
Europe (in particular Northern Europe), which appear likely to have high prevalence’s of 
endometriosis (i.e. equal to or higher than the standard 10% rate) based on the risk factors analysed. 
Southern America, China, Indonesia and Southern Asia appear to be intermediate areas regarding 
endometriosis risk (i.e. Higher than Africa but lower that Northern Europe).  
The data on age at menarche shows a clear correlation between age at menarche and HDI. Due to 
early menarche being a major indicator of endometriosis risk it can thus be concluded that risk of 
endometriosis is related to HDI. This notion is supportive of the accuracy of the prediction model as 
HDI is also correlated with the theoretical ERI score (Figure 17). This is the first study of its kind to 
demonstrate a link between HDI and age at menarche.  
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The evidence presented in this chapter provides substantiation for the conclusions proposed above 
which indicate that women living in developed countries have a higher risk of endometriosis than 
those in developing nations. This is supported by the existing literature, which suggests that women 
of native African nationality are at the lowest risk of endometriosis whilst Caucasian European 
(particularly Northern Europeans) women at the highest risk. Hispanics and Asians were 
documented as having an intermediate level of risk [2-4], which provides further evidence for the 
accuracy of this model. Yet validation of its accuracy can only come as further real world data is 
gathered. It would be of significant interest to document any countries whose ERI score did not 
match those of real world data. Analysis of the demographic and lifestyle of a population of any such 
country may provide additional insight into factors underlying the development of endometriosis.  
 
Testing this prediction model would require the extrapolation of predicted prevalence data for a 
certain country and comparing this to actual data. Deriving an estimate of endometriosis prevalence 
for a certain country can be achieved by using the ERI score as a proportional representation of the 
prevalence of endometriosis in any given population of women of reproductive age. For example, it 
is widely reported that countries such as the United Kingdom and New Zealand have an 
endometriosis prevalence of 10% of women of reproductive age. Both these countries have an ERI 
score of 0.96, therefore it is reasonable to conclude that countries with of ERI of 0.96 will have an 
endometriosis prevalence of 10%. If it is supposed that endometriosis prevalence decreases 
proportionally with ERI then we have a method of producing testable endometriosis prevalence’s 
(represented by a percentage of population of females of reproductive age) from this prediction 
model.  Taking this further, if the estimated prevalence’s of endometriosis are known, then it would 
be possible to estimate the number of endometriosis sufferers in any country for which the ERI is 
known. Table 5 below illustrates some examples of predicted endometriosis prevalence’s for 
selected countries. 
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Country ERI Score Predicted 
Endometriosis 
Prevalence (%) 
Female Population 
of Reproductive Age 
(15-60) [211] 
Predicted 
Endometriosis 
Prevalence 
(individuals) 
United 
Kingdom 
0.96 
 
10.0% 20,185,040 
 
2,018,504 
 
United States 0.92 9.6% 102,161,823 
 
9,790,508 
 
Brazil 0.76 7.9% 66,157,812 
 
5,237,493 
 
Japan 0.72 7.5% 40,894,057 
 
3,067,054 
 
China 0.60 6.3% 465,020,030 29,063,752 
Pakistan 0.52 5.4% 48,921,023 2,649,889 
India 0.44 4.6% 352,868,003 16,173,117 
Bangladesh 0.36 3.8% 47,468,013 1,780,050 
Niger 0.32 3.3% 3,267,496 108,917 
 
Malawi 0.24 2.5% 3,563,840 
 
89,096 
 
 
These results give testable predictive values for the number of individuals that suffer from 
endometriosis. It would therefore be possible to compare actual endometriosis population data with 
these data to test the accuracy of this model. At the time of writing there is only one publication that 
affords this opportunity.  
2.5.1. Proof of Concept 
A recent publication by Gylfason et al [212] reported the incidence of endometriosis in an Icelandic 
population over 20 years, this data allows the comparison of real world and predictive endometriosis 
prevalence. The population of Iceland is relatively homogenous, composing primarily of Nordic-
Caucasians. The authors noted that women participating in this study originated mainly from the 
urbanised capital ensuring similar living conditions, diet and standard of living [212], thus making it  
an ideal sample population to test the prediction model. Gylfason et al reported an incidence of 
1,303 women diagnosed with endometriosis, in the age group 15-49, between 1981-2000. The 
Table 5. Predicted Endometriosis Prevalence for Selected Countries 
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National Statistical Institute of Iceland [213] gives the female population for this age group and date 
range to be 15,325 giving an endometriosis incidence rate of 9.0% over 20 years. To test the model 
the predicted ERI score needs to be converted into a percentage of population. The United Kingdom 
has a predicted ERI score of 0.96, and a known endometriosis prevalence of 10.0%. It is therefore 
reasonable to conclude that an ERI score of 0.96 is equal to a prevalence rate of 10%. Therefore, by 
decreasing the % prevalence proportionally to the ERI we can predict the % prevalence in a country. 
Using this method predictive and known % prevalence for endometriosis can be compared based on 
the data for Iceland.  
 
The ERI score for Iceland was 0.92 equating to a reduction of 4% on the 0.96 ERI for the UK. If we 
proportionally decrease the % prevalence we arrive at a predicted percentage prevalence of 9.6%. In 
terms of number of women with endometriosis this led to a predictive value of 1,469 women with 
endometriosis. Comparing this to the real world data recorded in Iceland gives an accuracy of 88.7% 
for the prediction model in this population.  
 
2.5.2. Limitations 
The conclusions that have been made in this chapter have limitations, such as the disparity between 
dates when certain data were collected. For example, the data for age at menarche in Britain was 
collected in 1986 whereas the Bangladesh data was collected for 1993. Due to the observed 
downward trend in age of menarche in developed countries over the last century [214], ideally it 
would be better to obtain data for age at menarche for the same time periods for each country.  
 
The prediction of endometriosis prevalence is also limited by the risk factors that have been chosen. 
For example, each risk factor cannot be weighted equally i.e. parity is much more influential on the 
risk of developing endometriosis than ovarian cancer incidence, however presently there is 
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insufficient evidence to accurately weigh each risk factor. Therefore, without an objective method of 
weighting the risk factors it is impossible to correct for any weighting errors that may occur. 
Nevertheless, evidence collected so far affords a compelling argument for the variation in 
endometriosis prevalence throughout the world.  
 
A further limitation may be the exclusion of certain risk factors due to lack of available data as 
mentioned in the discussion. For example, dioxin or other EDCs may play a significant role in the 
development of endometriosis, but with data on EDC exposure limited, it cannot be accounted for in 
this prediction model. 
 
Additionally, this prediction model assumes that all populations are homogenous, however this is 
not the case. The USA and UK, for example, comprise a large diversity of ethnicities and cultures, all 
of which have differing levels of the risk factors used to create this model of prediction. For example, 
this model indicates that the UK would have a high prevalence of endometriosis based on the risk 
factors applied such as low parity and high alcohol consumption. However, the Muslim population of 
the UK would consume little to no alcohol and an orthodox Catholic family would be expected to 
have a high number of children. Hence, these populations within the UK would be expected to have 
a lower prevalence of endometriosis. Therefore, it must be taken into account that this model can 
only estimate the prevalence of endometriosis for the population of a country as a whole. The 
prevalence of endometriosis within sub-populations is likely to significantly vary.   
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Chapter 3. Of Epigenetics and Endometriosis 
 
3.1. Background 
Epigenetics is a relatively new field of science. Over the last 20 years in particular, scientific 
investigation into epigenetic mechanisms has expanded exponentially. Figure 23 shows the rapid 
increase in publications with the keyword ‘epigenetics’ in the title over the last 22 years according to 
the PubMed database.  
 
 
Epigenetics is defined as heritable changes in gene expression that are not associated with changes 
in the nucleotide sequence. More recently epigenetics has been used as an umbrella term for all 
processes, factors and interactions that alter transcriptional regulation or expression of a gene 
without changing the DNA code, and many describe it as an additional ‘layer’ of transcriptional 
regulation. Any cell within the body contains the same genetic information, however individual cell 
types display a wide variety of functions and morphology. Epigenetic mechanisms allow cells to be 
‘programmed’ to perform specific functions and specialised by regulating the genetic expression of 
information. For many years the Zeitgeist among geneticists was that heritable change can only be 
mediated via a change in nucleotide sequence. Epigenetics has changed this preconception by 
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Figure 23. Epigenetic publications over the last 22 years 
 51 
 
showing that it is not just the sequence of DNA, but the marks it carries that can result in heritable 
phenotypic changes. Recently there have been several publications concerning the involvement of 
epigenetic mechanisms in endometriosis [69], this chapter will explore and build upon this current 
knowledge. 
3.1.1 DNA Methylation 
Methylation is perhaps one of the most widely studied epigenetic marks. A methyl group can be 
bound and removed from the 5’ carbon of a cytosine on a CpG dinucleotide in DNA. If a region of 
DNA contains a large portion of CpG dinucleotides it is referred to as a CpG island. Methylation 
controls the expression of genes by altering the structure of chromatin. Chromatin is comprised of 
DNA wrapped around a core of eight histone proteins (two sets of H2A, H2B, H3, H4 which can also 
be methylated), this together is known as a nucleosome [215]. The packing of these nucleosomes 
defines the structure and nature of chromatin. Active chromatin (euchromatin) is characterised by 
low levels of histone and DNA methylation and high levels of histone acetylation and has an open 
structure allowing access of transcription factors and polymerase enzymes. Tightly packed chromatin 
(heterochromatin) is characterised by highly methylated histones and DNA and low levels of 
acetylation and is transcriptionally inactive (Figure 24). If the CpG dinucleotides are methylated in a 
particular gene (usually in the promoter region) [216], the gene may become silenced or down 
regulated [217, 218]. Conversely, if the CpG islands in a gene promoter remain unmethylated, the 
gene will be more highly expressed [217, 218]. A significantly high percentage of all the CpG islands 
in the genome in any one cell type, at any one time display high levels of methylation, with 
estimates of 60-90% of all CpG residues being methylated [219]. These modifications are reflective 
of the fact that, in any one cell type, only tissue specific genes need to be active. Activation of the 
wrong gene in the wrong cell type may lead to the onset of diseases such as cancer or the 
development of other fatal abnormalities. The only exceptions to suppression by methylation are 
‘housekeeping’ genes, which are essential for generic cell functions and are therefore constituently 
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activated in the majority of cells. The DNA of these housekeeping genes is mostly hypomethylated 
[220], reflecting their need for consistent activation. 
 
 
 
 
 
 
 
 
 
 
 
 
The establishment of DNA methylation patterns is an active process, which is applied and 
maintained by DNA methyltransferase (DNMT) enzymes of which, there are three main isozymes in 
mammals, DNMT1, DNMT3a and DNMT3b. The universal methyl donor S-adenosyl-L-methionine 
(SAM) is required by the DNMT enzymes for the transfer of a methyl group to the C5-position on a 
cytosine residue. It is now recognised that the reaction is a Michael addition, whereby the Pro-Cys 
dipeptide of motif IV is the cysteinyl thiolate that covalently binds the C6 position of cytosine. A 
glutamyl residue of conserved motif VI protonates cytosine N3, which generates a reactive cytosine 
4,5 enamine. This enamine attacks the sulphonium-linked methyl group of SAM. The methyl group is 
Histone Core 
DNA strand 
Open ‘Active’ Euchromatin 
Condensed ‘Inactive’ Heterochromatin 
Unmethylated CpG 
Methylated CpG 
Acetylated Histone 
Methylated Histone 
Figure 24. The relationship between histone and DNA methylation and chromatin structure.  
 
Transcriptionally active Euchromatin, shown above, displays an open structure, the CpG islands in the DNA are 
unmethylated and the histones are acetylated. Heterochromatin displays a more condensed and transcriptionally 
inactive structure with methylated CpG islands and histones. Adapted from Epigenetics by J.Tost (2008) Caister 
Academic Press 
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transferred and a proton is removed from C5 resulting in the reformation of the double bond 
between C5 and C6. This results in the release of the enzyme by β elimination [221-223]. DNMT1 is 
responsible for copying and maintaining the existing pattern of methylation during cell replication 
[224], DNMT3a and DNMT3b introduce new methylation patterns and are thus known as the de 
novo methyltransferases [225], and recently DNMT2 and DNMT3L have been identified. Although 
the exact function of DNMT2 has yet to be fully characterised, some evidence suggests it has weak 
methyltransferase activity [226], not only for DNA but also for tRNA [227], however what biological 
function this serves has yet to be elucidated. DNMT3L appears to lack methyltransferase activity but 
evidence suggests it acts as an enhancer for DNMT3a and DNMT3b [228]. The pattern of DNA 
methylation laid down during gametogenesis and embryogenesis is essential for survival. Mice that 
have been engineered to show a dramatic loss of DNMT1 function presented with reduced weight at 
birth and rapidly developed aggressive T cell lymphoma [229].  Mouse knockouts for DNMT3a and 
DNMT3b proved similarly fatal [225] but with significantly earlier mortality than those with a single 
knockout.  
 
It also appears that DNMTs function synergistically since disruption of DNMT3b only resulted in a 3% 
reduction in total global DNA methylation [230]. However, simultaneous disruption of DNMT1 and 
DNMT3b results in an almost total loss of methyltransferase activity and subsequent DNA 
methylation [230]. Further evidence for the co-activity between the DNMT enzymes was provided by 
Kim et at [231], who found that the N-terminus of DNMT3A and DNMT3B bind to the N-terminus of 
DNMT1 [231] and the co-expression of all three DNMT enzymes enhanced the activity of DNMT1 
[231]. Collectively, this evidence suggests that full functionality and co-operation of DNMTs is 
essential for successful development and survival. 
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Recently it has been shown that DNMT1, DNMT3a and DNMT3b are over expressed in endometriotic 
tissue [232, 233]. These findings are likely to provoke new ideas regarding the origin and aetiology of 
endometriosis. For example, over-expression of these enzymes would be expected to alter global 
DNA expression in endometriotic cells. DNA microarray analysis of endometriotic tissue supports this 
expectation since a substantial number of genes display significantly altered expression patterns 
[234-239]. Another possible explanation for these observed irregularities in gene expression may be 
due to abnormalities in the regulation and function of the major transcription factor, NF-κB, in 
endometriosis (for review see Guo 2007 [240]). While this may be so, the introduction of epigenetics 
into the fray offers new insights into the origin and progression of disease, such as the combined 
effect of disrupting traditional and epigenetic regulators of transcription. In support of this notion 
Wren et al [241] demonstrated that epigenetic mechanisms such as histone modifications, 
methylation and acetylation may play a role in the aetiology of endometriosis. However, results from 
microarray studies provide an unusual paradox. The majority of studies found almost the same 
number of down regulated genes as there were up regulated in ectopic endometrial tissue. For 
example, Kao et al [235] reported 91 genes significantly over expressed and 115 under expressed. 
Similarly Eyster et al 2002 [237] and Eyster et al 2007 [234] reported more genes over expressed in 
ectopic endometrial tissue. Yet enhancement of DNMT function in endometriosis should lead to 
increased levels of DNA methylation hence, increasing the number of silenced or down regulated 
genes. This raises the question as to how a system can be in place where global gene expression in 
endometriotic cells should be down-regulated by over active methylation, and yet the evidence 
clearly shows many genes are up-regulated. However, it should be noted that Burney et al reported 
a higher frequency of under expressed genes in the eutopic endometrium of women with 
endometriosis vs disease free controls. A possible explanation to this paradox will be discussed in 
section 3.6. Of course it must be considered that not all genes are epigenetically regulated, genetic 
mechanisms are likely to play a significant role in aberrant gene expression in endometriosis.  
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It could be hypothesised that over-expression of DNMTs causes several key genes involved in 
regulating cell growth and apoptosis to be silenced or under-expressed, leading to the survival and 
proliferation of endometriotic cells. This is indeed the case for cancerous cells as demonstrated by 
Jacinto et al using HCT-116 colorectal cancer cells [242]. Current evidence may indicate a similar case 
for endometriosis, as endometrial cells from women with endometriosis display reduced apoptotic 
markers [243] and a reduction in the expression of pro-apoptotic genes [244] when compared with 
controls. Indeed, this apoptotic resistance is evident for many types of malignant cells where DNMTs 
are also frequently over-expressed [245].  
 
Discovery of the over-expression of DNMTs in endometriosis may lead to new therapeutic regimens. 
DNMT inhibitors have already been developed for the treatment of cancer, with compounds such as 
5-aza-2’-deoxycytidine proving effective at reducing tumour growth in human trials [246]. This anti-
tumour effect is thought to be due to restoration of a previously hypermethylated tumour 
suppressor genes to its active state. This effect could potentially be exploited for the treatment of 
endometriosis by restoring both the expression of the hypermethylated progesterone receptor [247] 
and the pro-apoptotic actions of the p53 gene, which is reportedly down regulated to near 
undetectable levels in endometriotic cells [248]. Despite the benefits promised by these new 
treatments, concerns regarding the use of such drugs were raised. Since they activate tumour 
suppressor genes, they could also potentially activate proto-oncogenes, counter-intuitively 
increasing tumour occurrence. Fortunately, evidence suggests that therapeutic use of demethylating 
agents does not appear to increase tumour incidence [249], although far more evidence is needed 
before these drugs can be declared safe for mass use. The potential application of these drugs for 
the treatment of endometriosis, given the evidence provided, is therefore worthy of further 
investigation.  
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3.1.2 Epigenetic Modification of Steroid Synthesis and Receptors in Endometriosis 
The deregulation of DNMTs is not the only evidence supporting the hypothesis that epigenetics plays 
a major role in endometriosis. Izawa et al [250] demonstrated that the expression of the cytochrome 
p450 aromatase enzyme (CYP19) is dependent on the methylation status of its promoter by treating 
endometriotic cells with the demthylating agent 5-aza-deoxycytidine and observing the fold change 
in aromatase mRNA expression. Current studies have reported either a weak or no association 
between polymorphisms of the aromatase gene and endometriosis [251-253] that could account for 
the observed over expression of aromatase in endometriosis. Those studies that have associated 
certain aromatase polymorphisms with endometriosis have been criticised for faulty data analysis or 
non reproducible results [254].  
 
Aromatase is a key enzyme involved in the synthesis of estrogen and plays a crucial role in the 
pathogenesis of endometriosis. With the exception of two studies [255, 256] aromatase is reported 
to be highly up regulated in endometriotic cells whilst being nearly undetectable in normal 
endometrium [106, 257]. The importance of aromatase in the pathology of endometriosis is aptly 
demonstrated by the use of aromatase suppressing drugs for the treatment of the disease. This class 
of drugs, although with limited clinical data, have shown to be effective in the symptomatic 
treatment of endometriosis [122-124]. Aromatase is normally expressed in a cyclic fashion 
throughout the menstrual cycle in eutopic endometrium however, expression levels are consistently 
elevated in endometriotic cells [258]. If the over-expression is initiated by hypomethylation of the 
promoter [250] and maintained by aromatase activating cytokines such as IL-6, IL-11 and TNFα, all of 
which have been shown to be dysregulated in endometriosis [39, 257, 259], a consequence would 
be over-expression of aromatase leading to increased synthesis of estrone, which is converted to 
estradiol, a potent estrogenic factor that initiates a number of pathways leading to the proliferation 
and survival of endometriotic cells [114]. The conversion of estrone to estradiol is catalysed by the 
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enzyme 17β-hydroxysteroid dehydrogenase type 1 (17βHSD I), which is reportedly up regulated in 
endometriosis [260]. The increased activation of aromatase in endometriotic cells leads to a self 
sustaining positive feedback loop for estradiol production, whereby prostaglandin E2 (PGE2) activity 
induces the up regulation of aromatase [258] leading to increased estradiol levels. In turn, this leads 
to the up regulation of the cycloxygenase-2 enzyme (COX-2) [261] resulting in the formation of more 
PGE2, an important factor in the pathology of endometriosis [262] thus the cycle becomes self 
perpetuating (Figure 25).  
 
 
 
 
 
 
 
 
 
 
 
Aberrant methylation of the aromatase promoter is not the only factor altering gene expression due 
to epigenetic alterations in endometriosis. Regulation of aromatase is mediated by steroidogenic 
factor-1 (SF-1) which is the aromatase enhancer, and chicken ovalbumin upstream promoter 
transcription factor (COUP-TF) [114] which is its repressor. Indeed, SF-1 has recently been shown to 
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Figure 25. The aromatase cycle.  
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Adapted from; Endometriosis in Clinical Practice, by David Olive (2005) Taylor and Francis 
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be over-expressed in endometriotic cells [263]. An explanation for the apparent over-expression of 
SF-1 has been proposed by Xue et al [264] who observed hypomethylation of the CpG island near to 
its promoter region. The discovery of epigenetic modifications in the promoters of aromatase and its 
enhancer SF-1 provide some understanding of the establishment of the reported positive feedback 
loop. As with mutations, once these epimutations are established, they are retained throughout 
each cellular division, ensuring the survival of the endometriotic cells.  
 
It is not only the synthesis of estrogen that is affected by aberrant methylation in endometriosis. In 
order for estrogen to mediate its mitogenic effects within the cell it must first bind to its receptor, of 
which there are two variants, estrogen receptor α (ERA) and estrogen receptor β (ERB) coded for by 
separate genes. Cells that over express estrogen receptors are highly sensitive to estrogenic effects. 
Such cell types include breast and ovarian cancer cells [265, 266] which, as with endometriotic cells, 
possess an enhanced proliferative capacity. Recent studies have shown that the mRNA of one 
isoforms of the estrogen receptor (estrogen receptor 2 gene, encoding estrogen receptor β) is over 
expressed in endometriosis [267]. This apparent over-expression was found to result from 
hypomethylation of the CpG islands in the promoter of the ESR2 gene. ERB is important as it is 
known to regulate several genes involved in signal transduction, cell cycle progression and apoptosis 
[268], however in contrast to endometriosis several studies have shown ERB to be down regulated in 
ovarian cancer [269, 270] and it thought that loss of ERB expression may induce malignant 
transformation [271]. It is also important to note that several endocrine disrupters though to be risk 
factors for endometriosis mediate signalling cascades via ERB [272, 273]. Therefore, not only does 
epigenetic modification lead to enhanced estrogen production but it also leads to increased 
sensitivity towards estrogen and estrogen-like compounds in endometriotic cells, resulting in a self 
sustaining endometriotic cell population.  
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Due to abnormal estrogen synthesis and metabolism observed in endometriosis, progestogenic 
agents are commonly administered to women with the disease in order to suppress endometriotic 
cellular proliferation by down regulating estrogen production and acting as an anti-inflammatory 
agent [274]. The efficacy of progestogens in relieving persistent pain symptoms associated with 
endometriosis is relatively poor [275], and a reported 9% of women are completely unresponsive to 
progestogen treatment [118].  The relative inefficiency or total lack of response to progestogenic 
treatment has thus, led some to conclude that endometriotic cells are somehow resistant to the 
effects of progesterone. Evidence for this comes from studies of the progesterone receptors in 
endometriotic cells. As with ER, there are two progesterone receptor isoforms, PR-A and PR-B. 
Unlike the ER, these encode as splice variants of the same gene and each has distinct functions and 
distinct levels of expression in the eutopic endometrium, depending on the phase of the menstrual 
cycle. PR-B is a transcriptional activator for several genes containing a PR-B dependent promoter. 
PR-A, on the other hand is a transcriptional repressor for PR-B and ERα [276]. Studies have shown 
that PR-B expression is absent, and only very low levels of PR-A are expressed in endometriotic cells 
[110], offering some explanation for progesterone resistance in endometriosis. Additionally, Wu et al 
[247] showed that the aberrant hypermethylation of the PR-B promoter, reduces its expression to an 
almost silenced state. PR-A and PR-B, although coded by the same gene, have distinct promoters, 
thus it may be possible that aberrant methylation of the PR-A promoter may be responsible for its 
reduced expression. Conversely Wu et al suggested that alteration of PR-A expression may not be 
due to altered methylation of its promoter, but is likely due to other as yet, unknown mechanisms. 
Nevertheless, it is reasonable to conclude that there are epigenetic mechanisms by which estrogen 
production is both enhanced and unopposed in endometriosis (Figure 26).  
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3.1.3 HOXA10 in Endometriosis 
HOX are a family of genes containing homeobox domains that act as transcription factors essential 
for regulating genes associated embryonic development. Several members of the HOX gene family 
play crucial roles during embryogenesis [277], for example HOXA9, HOXA10, HOXA11 and HOXA13 
are involved with the development of the female reproductive tract, and unlike the majority of HOX 
genes they are expressed into adulthood [278]. A novel feature of the HOX genes is that the 
positional location of the gene along the chromosome is related to the positional location of the 
organ for which it is responsible (Figure 27). The involvement of HOXA10 in the development of the 
uterus affords specific interest with regards to endometriosis since any aberrant expression of 
HOXA10 may result in abnormalities, in either the function or morphology of the uterus. HOXA10 
expression is reportedly down regulated in patients with endometriosis [279, 280], perhaps 
reflecting the findings that patients with endometriosis are more likely to present with anatomical 
complications of the reproductive tract [281, 282]. HOXA10 under-expression in endometriosis 
patients may also explain the associated subfertility observed in these patients since HOXA10 along 
with HOXA11 are responsible for successful implantation of the embryo [283, 284].  
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Figure 26. Epigenetic enhancement of estrogen sensitivity in endometriosis 
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The origin of the down regulation of the HOXA10 gene in endometriosis was investigated by Wu et al 
2005 [285] and Kim et al 2007 [286]. Wu et al’s study screened eutopic endometrium of women with 
endometriosis, whereas Kim et al screened eutopic endometrium from baboons with experimentally 
induced endometriosis. Both studies identified hypermethylation in the promoter region of the 
HOXA10 gene. However, these studies examined only methylation patterns of HOXA10 in the 
eutopic endometrium of endometriosis cases and controls, but did not examine the methylation 
status of HOXA10 in ectopic endometrium. Wu et al’s study was also confined only to women with 
stage III-IV endometriosis. Therefore, definite conclusions regarding the aberrant expression of 
HOXA10 in endometriotic tissue in humans cannot be made. However, a study by Lee et al 2009 
[287] using a murine model of experimentally induced endometriosis, found inducing endometriosis 
led to methylation dependant changes in HOXA10 expression in eutopic endometrium. This 
essentially turns current thinking on its head, as it has long been thought eutopic endometrium 
dictates the fate and function of ectopic endometrium (via polyclonal origin of ectopic endometrium 
from refluxed eutopic cells [288]) not, as Lee et al demonstrated, the other way around. Although it 
may be that interplay of signalling exists between the two cell types, the mechanism by which 
ectopic endometrium can influence epigenetic alteration of eutopic endometrium remains to be 
elucidated.  
Fallopian 
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Figure 27. HOX genes in the development of the Müllerian duct.  
Adapted from; Endometriosis in Clinical Practice, by David Olive (2005) Taylor and Francis 
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Interestingly, further study has reported that HOXA10 hypomethylation can be induced by in-utero 
exposure to diethylstilbestrol (DES) [289], a known endocrine disruptor. The ramifications of DES 
exposure are discussed further in section 3.5. The effect of altered HOXA10 expression in eutopic 
endometrium is obvious in terms of uterine morphology and embryonic implantation. What the 
biological significance of HOXA10 down regulation, in endometriotic tissue may be remains 
speculative. Some clues may arise from microarray study of HOXA10 knockdown cells, which 
reported HOXA10 as a regulator of hundreds of genes involved in a variety of cellular processes 
[290]. Of particular interest was the finding that HOXA10 knockdown led to a 5.78 fold increase in 
the CYP19 (aromatase) gene, the significance of which is discussed in section 3.2. It is also important 
to note that HOXA10 and HOXA11 are progesterone responsive genes (the significance of altered 
progesterone signalling is discussed in Section 3.1.2) and members of the HOX family themselves 
regulate a number of other genes including IGFBP-1 (see Section 3.1.4) and integrins (see Section 
3.1.7) [291] 
 
Nevertheless, the altered expression of HOXA10 in women with endometriosis may provide an 
explanation for one of the most puzzling aspects of endometriosis, which is, if retrograde 
menstruation is near universal, why do only a fraction of women develop endometriosis? It may be 
that HOXA10 aberrations result in improper development of the uterus. This is supported by the 
observed uterine anatomical abnormalities in women with endometriosis such as increased 
frequencies of septate uterus [292] and the reported decreased elasticity of the reproductive organs 
[282]. Both aspects are thought to increase the volume of menstrual reflux in some women, 
overwhelming the immune system which is thus unable to remove all the refluxed endometrial cells.  
3.1.4 Insulin-Like Growth Factors and Imprinting 
The insulin like growth factors (IGFs) are of particular importance when considering endometriosis 
since they are responsible for mediating the proliferative function of the endometrium. The 
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availability of IGFs is regulated by their association with IGF binding proteins (IGFBP) and IGFBP 
proteases. IGF-1 and IGF-2 are potent mitogenic factors and importantly, their expression is 
regulated by progesterone and estrogen [293]. Studies assessing the expression of IGF-1 in 
endometriosis  provide discordant results. Some authors report higher levels of IGF-1 in the PF of 
women with endometriosis [294, 295], whilst others report either decreased expression of IGF-1 
mRNA [296] or no change in expression [297]. However, a recent study of gene expression revealed 
that IGF-2 is significantly over expressed in endometriotic tissue [298]. A further investigation, which 
aimed to assess the differences in IGF expression between the eutopic and ectopic endometrium of 
women with endometriosis revealed that the expression patterns of IGF1 and IGF-2 in the ectopic 
endometrium were not synchronous with expression patterns in the eutopic endometrium and that 
the levels of eutopic expression varied between women with and without endometriosis [299].  
Previously in section 3.1.2 it has been discussed how estrogen levels can be increased in 
endometriotic tissue by the aromatase cycle, therefore it can be postulated that it is the increased 
level of estrogen that enhances expression of IGFs. However, an epigenetic mechanism that has 
been widely studied, may offer an alternative explanation for the over-expression of IGF-2 in 
endometriosis. This mechanism originates from studies of many different types of cancer [300] and 
is known as loss of imprinting (LOI). Imprinting refers to parent of origin specific allelic expression 
which means that only one copy of an imprinted gene (either the maternal or paternal) is expressed, 
and the other is silenced by methylation. In this case, for example IGF-2 is an imprinted gene that is 
normally only expressed from the paternal allele. LOI however cannot explain the aberrant 
expression of IGF-1 in endometriosis as it is not an imprinted gene. Imprinting can be lost by changes 
in the methylation status of an imprinted gene resulting in either both alleles being activated or 
silenced. The resulting gene product will be either over or under-expressed and occasionally, as in 
several cancers and possibly endometriosis, this abnormal expression can contribute to the 
molecular pathology of a disease, particularly when the gene is involved in cellular invasiveness or 
proliferation. In females it could be considered that an entire chromosome is imprinted due to the 
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inactivation of one copy of the X chromosome. Imprinted genes are therefore more fragile than 
others, as it only requires the activation or inactivation of one allele to alter the entire gene 
expression. LOI was first documented in Wilms tumour, a kidney tumour that predominately occurs 
in children [301]. LOI of the WT1 gene is known to be responsible for the development Wilms 
tumour. Interestingly, WT1 expression is reportedly down regulated in the eutopic endometrium of 
women with endometriosis [302], whether or not LOI is responsible for this down regulation 
warrants further investigation. It is worth considering that in Wilms tumour and other types of 
cancer, mutation is responsible for only 5% of cases where WT1 deregulation leads to disease 
presentation [300], and therefore LOI is likely the dominant means by which WT1 deregulation 
occurs. If this holds true for endometriosis then the argument for LOI of WT1 in women with 
endometriosis becomes very strong. Whether or not LOI is responsible for the differences in 
expression of IGF-2 in women with endometriosis also remains unclear however this hypothesis 
clearly warrants further exploration.  
 
Further investigation into the significance of imprinted genes within the genome revealed that the 
distribution of imprinted genes is not as sporadic as was first expected. Imprinted genes have been 
found to be closely flanked by others, forming clusters of imprinted genes at certain points in the 
genome. This led to the discovery that imprinted gene clusters can be regulated by an essential 
control sequence element known as an imprinting control element, or imprinting control region 
(ICR). The ICR that regulates IGF-2 for example, known as the Beckwith Wiedemann Syndrome (BWS) 
region, is also responsible for the control of nine other imprinted genes [303]. ICRs rely on 
methylation for control of repression or expression. IGF-2 for example, relies on methylation of the 
BWS ICR near the neighbouring gene H19 and is responsible for the selective IGF-2 expression on the 
paternal allele. The regulation of more than one imprinted gene by a single ICR has obvious 
implications in disease processes since one ICR alteration can produce knock on effects in many 
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genes. Since clusters of imprinted genes have differentially methylated ICRs [304], the control of 
imprinted genes is of great importance for understanding the aetiology of complex diseases such as 
endometriosis.  
3.1.5 Epigenetics and the Environment 
Epigenetics provides a link between genotype and the environment, and how exposures to different 
environmental, pharmacological and dietary elements can translate into heritable changes in gene 
expression. During early mammalian development the methylome is stripped and then re-applied in 
order to start development from a ‘blank state’ in which methylation errors are removed, for this 
reason it was thought that alteration of epigenetic marks such as methylation patterns could not 
effect subsequent generations. If epigenetic marks were heritable then the complex phenotypic 
consequences they encode, which may include disease phenotypes, must be heritable also. This 
leads to two issues that must be addressed before proceeding. Firstly, can epigenetic marks be 
altered by environmental influences and secondly, are these epimutations of the F0 generation 
transmissible to the F1 and F2? In order to answer the first question it is important to consider that 
epigenetic marks are vulnerable to alteration during the demethylation events that occur early in 
development but are also venerable to change during each cell replication. DNA methylation by 
DNMTs is dependent on methyl donors such as S-adenosylmethionine (SAM), the major methyl 
donor, which is synthesised as part of the methionine cycle. The formation of this cycle is, in turn, 
dependent on dietary factors such as folic acid, vitamin B12, choline and betaine. Animal studies 
have shown that restricting dietary methyl donors produces a reduction in DNA methylation [305, 
306], and in some cases, increased risk of developing tumours [307, 308], indicating that epigenetic 
aberrations mediated by dietary changes can result in complex disease phenotypes. The sparse 
epidemiological studies which have reported on the influence of diet and endometriosis [70] suggest 
that a diet high in fruit and green vegetables and low in meat and alcohol consumption is protective 
against developing endometriosis, however some findings were inconsistent [309]. From an 
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epigenetic perspective a diet high in fruit and green vegetables would provide a significant source of 
methyl donors, which may protect against demethylation induced genetic instability during foetal 
development [310, 311]. Alcohol consumption has been shown to alter histone acetylation and 
methylation patterns [312] which may account for the observed estrogenic effect of alcohol [313], 
There is also the effect of synthetic environmental toxicants on epigenetic states to take into 
consideration. For many years the involvement of dioxins in the pathophysiology of endometriosis 
has been debated as dioxin acts as an endocrine disruptor. By binding to, and activating the Aryl 
Hydrocarbon receptor (AhR), dioxin causes the transcriptional activation of genes involved in 
estrogen synthesis and this action [314] is thought to promote the proliferation of endometriotic 
cells. In particular it is important to note that there is significant cross talk between the AhR and the 
estrogen receptors [315, 316]; see section 3.1.2 for the significance of altering estrogen receptor 
expression in endometriosis.  Evidence for the role of dioxin in endometriosis resulting from animal 
studies has shown that primates and rodents exposed to high levels of dioxin exhibit an increased 
incidence of endometriosis [75, 317]. The validity of these data has however, been questioned [78], 
since the animal and human data are not robust, with the sample size and data analysis being called 
into question. A further criticism of the evidence is that only the effect on adults directly exposed to 
dioxin was taken into consideration, and that the incidence of endometriosis among their offspring 
was not reported. Nevertheless, evidence for the association between environmental toxin exposure 
and endometriosis continues to be an area of significant interest, with recent investigation focussing 
on the effect of body burden of organochlorides and their potential association with endometriosis. 
Several of these studies concluded that women with higher levels of organochloride exposure were 
not conferred an increased risk of developing endometriosis [318], while others demonstrated that 
women with endometriosis displayed higher serum levels of dioxin than controls [81, 82]. Thus, the 
implication of dioxin or other exogenous compound exposure in the development of endometriosis 
is sound in theory, but appears to lack definitive evidence. In particular, geographical areas where 
dioxin exposures have been high have reported no statistically significant increase in endometriosis 
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incidence. With regards to epigenetics, dioxin has been shown to alter the methylation status of the 
imprinted genes IGF-2 and H19 in mouse embryos [319] and therefore, may also alter the 
methylation status of other genes. However, the mechanism by which dioxin mediates this effect on 
methylation is unknown. This epigenetic alteration is maintained throughout gestation and into 
adulthood, demonstrating that dioxin exposure can have detrimental effects on the epigenetic 
status that may be heritable. However, further studies are needed to fully assess the effects of 
dioxin on epigenetic marks and the implications that any alterations may have in the 
pathophysiology of endometriosis.  
 
It is not just exposure to environmental toxicants during adulthood that requires consideration but 
also exposure in-utero. Missmer et al [3] showed that in-utero human exposure to diethylstilbestrol 
(DES) increased the risk of endometriosis by 80%, but small sample size has been cited as a limitation 
of this study. DES is a synthetic estrogen which was commonly used as an anti-miscarriage drug 
between 1947 and 1971 [320]. Further human exposure resulted from the supplementation of DES 
in cattle feed as a growth enhancer [321]. DES has previously been documented to cause uterine 
abnormalities in the offspring of women and animals exposed to in-utero [320, 322]. Additional 
studies implicate early exposure to DES in a range of reproductive disorders and cancer [323]. 
Exposure to DES reportedly increases the expression of DNMTs, which are known to be over 
expressed in patients with endometriosis [324] and the reported epigenetic alteration of HOXA10 
expression by DES has previously been discussed in section 3.1.3. Whether the over-expression of 
DNMTs in endometriotic tissue is the result of exposure to DES or other exogenous compounds is 
not certain. The preceding information provides substantiation for the hypothesis that dietary and 
environmental factors influence epigenetic states and may subsequently lead to disease 
presentation. 
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In order to complete the picture, the evidence for inducible epimutations being transmitted to the 
F1, F2 and beyond must be also be addressed. Several studies using rodents have hinted that complex 
disease traits can be transmitted to the F2 via non-genomic pathways due to exogenous compound 
exposure of the F0 [325-327]. Further study into such phenomena has revealed that the tumorogenic 
effects of DES are heritable in mice and humans [328, 329], possibly as far as the F2 [330, 331], 
mediated by alteration of proto-oncogene methylation, possibly providing an explanation for 
transmissible, DES induced endometriosis through family lines. Bruner-Tran et al [332] demonstrated  
that early exposure to dioxin during mouse development led to alteration of methylation patterns 
which subsequently led to the mice developing an endometriosis like phenotype. However, it was 
not stated whether this phenotype was present in the F1 or F2 of exposed mice. Dietary habits of the 
F0 have also been shown to affect epigenetic changes in subsequent generations. Initially, rodent 
studies demonstrated that maternal dietary restriction of methyl donors can translate to aberrant 
expression of several genes mediated by methylation in the F1 [333-336]. Historical occurrence of 
mass dietary restriction in human females in the Netherlands, during 1944-1945 famine, resulted in 
reduced birth weight and increased insulin resistance of the offspring [337, 338]. Conversely, male 
dietary abundance in Sweden in the late 19th century led to increased mortality due to diabetes in 
their paternal grandchildren [339]. Due to the transgenerational effects of diet, further investigation 
is therefore warranted into the dietary habits of the parents and grandparents of women with 
endometriosis. 
 
Due to the complex nature of endometriosis, diet alone is unlikely to be the main factor when 
considering the epigenetic involvement in endometriosis. However, the involvement that diet plays 
in the alteration of epigenetic states in endometriosis is a field worthy of study given the evidence 
that diet can influence deleterious epigenetic modifications and possibly contribute to the 
development of cancer [306].  
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The evidence presented here leads to the tantalising possibility that endometriosis can originate 
from epigenetic and hormonal modifications resulting from in-utero exposure to environmental 
estrogenic substances such as dioxin and DES, and furthermore, the epigenetic aberrations and 
therefore the disease itself becomes heritable. Further evidence is provided by a study that reported 
the effect of foetal and neonatal exposure to the endocrine disruptor Methoxychlor and its 
metabolites. This study concluded that early developmental exposure to these endocrine disruptors 
led to permanent alteration of the methylation states of the ESR2 promoter via up regulation of 
DNMT3B activity, ultimately leading to alteration of ovarian steroid production [272]. Thus, 
providing further evidence that endocrine disruptor exposure from environmental sources can lead 
to permanent epigenetic alterations that favour the development of endometriosis. This epigenetic 
hypothesis can link together many of the characteristics observed in endometriosis. In particular, the 
way in which endometriosis displays heritability, but can also arise with no family history. However, 
this is a double edged sword since not only can exogenous estrogens be harmful, they can also be 
beneficial. Studies of the plant isoflavone genistein have shown that it has protective effects against 
endometriosis by reducing the expression of ERα and increases expression of progesterone 
receptors [340]. A further investigation revealed that supplementation with genistein resulted in 
regression of endometriotic implants in animal models [188]. Therefore, the use of compounds 
analogous to genistein as a possible treatment for endometriosis should be considered.  
3.1.6 Micro-RNAs and Endometriosis 
Micro-RNAs (miRNA) are a class of small non-coding RNAs ~22 nucleotides in length. Since their 
initial discovery, over 500 individual miRNAs have been identified in the human genome [341] and 
more continue to be characterised. MiRNAs are included as an epigenetic mechanism since they 
possess the ability to regulate the expression of genes without altering DNA sequence. However, 
unlike the transcriptional repression action of DNA methylation, miRNAs act post-transcriptionally by 
binding to target sequences of mRNA. The way in which miRNA functions as a repressor is by 
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possessing a complimentary sequence to a specific protein coding mRNA. Upon binding to its target 
sequence the miRNA can interfere with the binding of polymerase or recruit endonucleases to break 
down the target mRNA (Figure 28).  
 
Regulation of genomic expression by miRNA is essential for development and survival [342]. This is 
not surprising considering it is estimated that around 30% of protein coding genes are regulated by 
miRNAs [343]. MiRNAs regulate a wide range genes involved in cellular functions such as 
proliferation, apoptosis, differentiation, development and regulation of the immune system [344-
346]. Regulation of miRNA expression is a finely controlled mechanism involving much the same 
transcriptional machinery as is involved in protein coding gene expression. There are several 
instances of miRNAs forming double negative feedback loops with regulators of miRNA transcription 
[347-351] adding an autoregulatory element to their expression. Recently however, it has been 
reported that miRNA genes can be epigenetically regulated themselves, by DNA methylation  [352-
354]. In particular a study by Saito et al [355] demonstrated that treatment of T24 bladder cancer 
cells with a combination of demethylating agent 5-aza-2’-deoxycytidine and histone deacetylase 
inhibitor, 4-phenylbutyric acid, led to ~5% of human miRNAs up regulated more than 3 fold. It is also 
worth noting that some miRNAs have tissue and developmental stage specific expression patterns 
[343] meaning that endometriotic cells are likely to have a specific pattern of miRNA expression, 
possibly aiding diagnosis or characterisation of endometriotic cells. It is therefore, noteworthy of the 
importance of miRNAs, not only in maintaining cellular function but also the potential for miRNA 
deregulation in contributing to disease presentation.  
 
Endometriosis has long been recognised as an immunological disease with the characteristics of 
chronic inflammation. Thus, it is important to consider the role of miRNAs in endometriosis due to 
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their regulation of normal immune function and their involvement in other inflammatory diseases 
[356]. At the time of writing there have been two well designed studies which analysed the 
expression of miRNAs in endometriosis. Pan et al 2007 [357] analysed the differential miRNA 
expression patterns of eutopic and ectopic endometrial cells. Analysis of 287 miRNAs detected in 
endometrial cells from women without endometriosis, paired eutopic, ectopic and unpaired ectopic 
endometrial cells identified 48 differentially expressed miRNAs in these tissues with a significant 
reduction in the levels of miRNA expression in disease tissue. This, in part, correlates with the finding 
that DNMTs are over expressed in ectopic endometrium, which may lead to hypermethylation of 
certain miRNA promoters, resulting in the observed reduction in their expression. 
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Figure 28. Biogenesis and mode of action of miRNAs.  
Adapted from Epigenetics by J.Tost (2008) Caister Academic Press 
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The authors also observed that ovarian steroids have a mediating effect on miRNA expression but 
the mechanism by which this occurs, is however unknown. Ohlsson Teague et al [358] using a similar 
methodological approach to Pan et al analysed the miRNA expression patterns in paired ectopic and 
eutopic endometrial tissue and identified 22 miRNA differentially expressed in ectopic tissue. 
However there is an interesting discrepancy between the two studies. The study by Pan et al found 
that all of the 48 miRNA’s aberrantly expressed in ectopic tissue were down regulated. Conversely 
Ohlsson Teague et al found, of the 22 miRNA’s aberrantly expressed, only 8 were down regulated 
and 14 were up regulated.  A possible explanation for these discordant results may arise from 
differences in methodology between the two studies. Firstly, Pan et al took tissue samples from 
disease free controls as well as paired eutopic and ectopic tissue. Ohlsson Teague et al did not take 
tissue samples from disease free women as controls, rather using paired eutopic and ectopic 
endometrium from the same woman. Secondly, Pan et al demonstrated that miRNA expression is 
regulated by ovarian steroids, therefore the menstrual phase in which the tissue samples were taken 
is likely to have a bearing on the miRNA signature of the tissue sample. Indeed Pan and Chengini 
reviewed the differential expression of miRNA’s during the menstrual cycle [359]. Significantly,  Pan 
et al’s study took tissue samples from women in the early-mid secretory phase, whereas Ohlsson 
Teague et al used samples from women in the follicular phase and secretory phase. It is particularly 
important to note that several authors have demonstrated that estradiol is an inhibitor of certain 
miRNA expression [357, 360, 361]. Therefore, increased levels of estradiol in the secretory phase 
and lower levels of estradiol in the follicular phase may account for the lowered expression of 
miRNA’s reported by Pan et al and higher expression reported by Ohlsson Teague et al respectively. 
 
These conflicting reports however, present a conundrum. It has previously been discussed that 
DNMT3A is over expressed in endometriotic tissue as reported by Wu et al 2007. DNMT3A is 
predicted as a target for miR-29c, therefore the reported up regulation of miR-29c by Ohlsson 
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Teague et al would appear contradictory to the finding of over expression of DNMT3A. An 
explanation for this may arise from the hormonal regulation of miRNA expression. If estradiol is 
inhibitory to miR-29c expression as it is with other miRNA’s it is then significant that the study by Wu 
et al took 23 out of 25 tissue samples from women during the proliferatory or secretory menstrual 
phases when circulating estradiol levels would be high, this in turn would lead to down regulation of 
miR-29c and allow for increased expression of DNMT3A.    
It is therefore possible that over expressed DNMTs either reduces miRNA expression directly by 
altering the methylation pattern of their promoters, or via an indirect mechanism that modulates 
the production of ovarian steroids. This also provides an explanation for the paradox mentioned in 
section 3.1 whereby increased DNMT activity may lead to genome wide over-expression of different 
genes in endometriosis. MiRNA expression, like gene expression, is regulated by methylation of CpG 
dinucleotides. Therefore, enhanced DNMT activity would result in the hypermethylation of a 
number of genes including miRNA genes. If this process silences or reduces expression of various 
miRNAs, then the ability of miRNA to inhibit their target gene is hindered; in effect enhancing the 
function of DNMTs can silence the silencers. The singular and combined effect of the abnormal 
expression of both DNMTs and miRNAs in ectopic endometrial cells may also explain the results from 
microarray studies conducted using eutopic and ectopic endometrium, which showed hundreds of 
genes aberrantly expressed, contributing to the complex and multifactoral nature of endometriosis. 
What are therefore, the implications of disrupting miRNA in endometriosis? 
3.1.7 Can Epigenetics explain the Malignant Potential of Endometriosis? 
Despite being a benign condition, endometriosis shares many characteristics with cancer. Indeed 
some authors have shown that endometriosis, particularly of the ovary (endometrioma), is prone to 
malignant transformation [362-365] with normal lifetime risk of developing ovarian cancer increased 
from 1.5% to 5-10% in women with ovarian endometriosis  (the pioneering Dr Sampson was the first 
to report such a case in 1925 [366]).  However, increase in risk is relatively small and cases that 
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match the criteria for direct malignant transformation of endometriosis are rare [367]. Women with 
endometriosis are not considered to be more at risk from cancer in general but evidence is 
accumulating to suggest that women with endometriosis may be at an increased risk of specific 
malignancies, including ovarian cancer, melanoma [368, 369] and non-Hodgkin’s lymphoma [370, 
371], however not all studies are concordant. The main limiting factor for studies examining 
associations between endometriosis and malignancies is small sample size, which leads to larger 
margins for error when judging associations. In light of this the Swedish National Board of Health 
and Welfare began collecting detailed medical records for discharges in an inpatient register from 
1964. From this data several cohort studies have been extrapolated. The first study analysed the 
records for 20,686 patients hospitalised for endometriosis from 1969 to 1983 [154] and linked them 
to the National Swedish Cancer Registry to detect subsequent incidences of cancer. Significant risk 
increases were found for breast cancer, ovarian cancer and hematopoietic malignancies (mainly 
representative of non-Hodgkin’s lymphoma). In particular it appeared that risk of developing ovarian 
cancer was related to duration of an existing case of ovarian endometriosis. Expansion of this study 
[372] included 64,492 women and confirmed the previous studies findings with the further inclusion 
that women with endometriosis appeared to have a decreased risk of cervical cancer. 
 A possible explanation for malignant transformation of endometriosis could be that the acquisition 
of endometriosis relies on a stepwise accumulation of genetic and epigenetic aberrations, with only 
a few mutational steps separating endometriosis and malignancy (Figure 29).   
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Chromosomal aberrations, such as loss of heterozygosisity (LOH) [373] and microsatellite instability 
[374] detected in endometriotic cells may indicate a genetically unstable state precluding them to 
malignant transformation. Studies indicate different types of endometriosis are more susceptible to 
malignant transformation. Ovarian endometriosis, for example, accounts for 75% of cases of 
tumorogenesis arising from endometriosis [375], this is supported by the finding of a higher 
frequency of chromosomal aberrations in ovarian endometriosis [376], suggesting it is more 
genetically unstable. Extraovarian endometriosis has been documented as undergoing malignant 
transformation but at a much rarer incidence [377].  Similarly, mutation leading to down regulation 
of tumour suppressor genes PTEN [378] and p53 [379] and over expression of oncogenes c-myc, c-
erbB-1 and c-erbB-2 [380] have been observed in endometriotic cells, which may increase the 
proliferatory nature of endometriotic cells and may also contribute to their malignant potential. An 
elegant study by Dinulescu et al demonstrated a stepwise progression from endometriosis to 
malignancy [381]. Female mice were engineered with an oncogenic allele of K-ras. These mice 
subsequently developed an endometriosis-like phenotype. Additional mutational deletion of PTEN 
induced a shift from an endometriosis-like phenotype to an ovarian endometrioid tumour, 
effectively demonstrating the transfer between disease states. Like endometriosis, over expression 
of DNMT’s has been documented in a number of malignancies [382-386]. The over activity if DNMTs 
is thought to silence tumour suppressor genes, contributing to cancer progression [242, 387, 388]. 
This has been the basis for using demethylating agents for the treatment of cancer, which has led to 
some encouraging results [389, 390] and provides further evidence for the use of such agents in the 
treatment of endometriosis.  
 
Endometriosis, like cancer, also displays metastatic potential. The expression of structural adhesion 
molecules such as cadherins are reported to be similar between endometriosis, ovarian 
endometrioma and borderline tumour [391]. Additional analysis of the expression of integrins, 
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another type of adhesion molecule, revealed that their expression was highly variable in 
endometriotic cells [392], whereas in normal endometrium their expression is tightly aligned with 
the phases of the menstrual cycle [392]. The abnormal expression of such molecules is thought to be 
an indicator of cellular dissemination and invasiveness [393] and is characteristic to both 
endometriotic and cancerous cells. In summary, there are several examples of epigenetic 
mechanisms being involved in the aetiology of endometriosis that need to be explored. The 
following studies will attempt to address and extrapolate novel data on these issues.  
3.2 Aims 
3.2.1. Insulin like Growth Factors and Imprinting 
The aim of this study was to assess the potential for the involvement of LOI in endometriosis. 
3.2.2. MicroRNAs and Endometriosis 
The aim of this study is to analyse the miRNA data on endometriotic cells from the studies by Pan et 
al and Ohlsson Teague et al to elucidate possible implications of miRNA disruption in the aetiology of 
endometriosis. 
3.2.3. Can Epigenetics explain the Malignant Potential of Endometriosis? 
The aim of this study is to assess the possible involvement of epigenetic mechanisms in the 
malignant transformation of endometriosis. Similarities in miRNA patterns between the two diseases 
will be the main focus.  
3.3 Methods 
3.3.1 Insulin like Growth Factors and Imprinting 
To date around 80-100 imprinted genes have been identified in humans and mice. A full database of 
these imprinted genes can be found at http://igc.otago.ac.nz/home.html [394]. In order to 
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investigate the possibility of any of these imprinted genes being disrupted in endometriosis this 
database of imprinted genes was cross referenced with microarray data. Microarray data was 
sourced from the PubMed citation database (accessed 12/08/2008) using the keywords 
‘endometriosis’ and ‘microarray’. This initial search yielded fifty results, which were narrowed to 
three articles with relevant information, Eyster et al 2002 [237], Eyster et al 2007 [234] and Kao et al 
2003 [235]. All three studies used similar methods and obtained similar results. Further information 
on the function of any genes identified as being imprinted and disrupted in endometriosis was 
sourced from the Entrez Gene online database (accessed 21/02/2009).  
3.3.2 MicroRNAs and Endometriosis 
MicroRNAs disrupted in endometriosis were identified by searching the PubMed citation database 
(accessed 02/03/2009) using the keywords ‘microRNA’ and ‘endometriosis’. At the time of writing 
this search yielded four articles, these results were narrowed to two articles with relevant 
information, Pan et al [357] and Ohlsson Teague et al [358]. Both studies used similar methods 
however results of these studies differed in some respects. In order to investigate the aim each 
miRNA identified as being differentially expressed in endometriotic tissue was investigated for 
potential targets by using the Sanger institutes microRNA target prediction software [395].   This 
software utilises the miRanda algorithm to identify potential binding sites for a given miRNA in 
genomic sequences. The algorithm uses a weighted scoring system and rewards complimentarity at 
the 5’ region of the miRNA. Alignments where more than one base is mismatched at this region are 
discarded. Each potential target site in the 3’ UTR is also checked to see whether the site is 
orthologous to transcripts from other species, each target must be conserved between at least two 
species. Any miRNA targets that matched with immunologic factors were searched for using the 
PubMed database using the keywords ‘endometriosis’ and ‘name of immunologic factor’.  
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3.3.3 Can Epigenetics explain the Malignant Potential of Endometriosis? 
Firstly the relationship between endometriosis and cancer was reviewed by searching the PubMed 
citation database using the keywords ‘endometriosis’ AND ‘cancer’ (accessed 29/04/2009). Secondly 
information was gathered on the involvement of epigenetic mechanisms in cancer and 
endometriosis by searching PubMed citation database (accessed 15/05/2009) with the keywords 
‘ovarian cancer epigenetic’ and ‘endometriosis epigenetic’. The relationship between miRNA 
expression patterns in endometriosis and cancer was investigated by cross referencing the miRNA 
data on endometriosis by Pan et al [359] and Ohlsson Teague et al [358] with data on the miRNA 
signature of cancer reviewed by Calin et al [396] and Corney et al [397].  
3.4 Results  
3.4.1 Insulin like growth factors and imprinting 
The results of this analysis identified two imprinted genes: Ankryrin repeat and SOCS box containing 
4 (ASB4) [398], and Brain-enriched guanylate kinase-associated protein (BEGAIN) [399] that were up 
regulated in endometriosis by 2.0 and 3.9 fold respectively.  
 
The protein product of the ASB4 gene, located in chromosome 7q21, was identified as a member of 
the ankyrin repeat and SOCS box containing family. The SOCS box serves to couple suppressor of 
cytokine signalling (SOCS) proteins and their binding partners with the elongin B and C complex, 
possibly targeting them for degradation. The  BEGAIN gene, located on chromosome 14q32.2, is 
reportedly a member of the NMDA receptor associated proteins which is involved in the assembly of 
neuronal synapses [400].  
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3.4.2 MicroRNA and Endometriosis 
Pan et al demonstrated that several of the miRNAs deregulated in endometriotic tissue meditate the 
expression of estrogen and progesterone receptors. The epigenetic implications of this deregulation 
of ER and PR have previously been discussed in section 2.2. Pan et al also found that two of the 
miRNAs that mediate aromatase mRNA (miR-23a and miR-23b) down regulated in endometriotic 
cells. This could mean that not only does hypomethylation of the aromatase promoter increase gene 
transcription, but down regulation of these miRNAs could result in enhanced translation of 
aromatase mRNA transcripts. However, Pan and Ohlsson Teague did not thoroughly examine the 
inflammatory and immune systems under the control of miRNA that are implicit in the pathogenesis 
of endometriosis. During retrograde menstruation, the refluxed endometrial cells are normally 
cleared by the immune system. However, perturbations in the immune response observed in 
women with endometriosis are thought to provide a permissive environment in which viable 
endometrial cells are allowed to proliferate. Prospective immune system abnormalities include 
reduction in the efficiency of natural killer (NK) cells against ectopic endometrium [401] and 
diminished T cell proliferation [402]. It is interesting to note that of the 13 of the 48 significantly 
altered miRNAs identified by Pan et al and 2 of the 8 miRNAs identified as under expressed by 
Ohlsson Teague et al in ectopic endometrial cells, were involved in the differentiation of T cells 
[344], specifically CD8+ and CD4+ T cells. This provides a possibly explanation for the observed 
reduced number of activated CD8+ and CD4+ T-lymphocytes in the peritoneal fluid of women with 
endometriosis [403].    
 
The effects of altered miRNAs expression may also have an indirect effect on T cell differentiation. 
Some authors have rightly pointed out that the aberrant expression of certain cytokines that 
regulate T cell and NK function are altered in endometriosis [404]. These cytokines such as IL-6, IL-8, 
IL-1, IL-1β, TNFα, INFγ, and TGF [39, 43, 405-408] are also regulated by miRNAs that are known to be 
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deregulated in endometriosis.  These cytokines can be secreted from leukocytes and from 
endometriotic cells themselves. The miRNAs shown to be aberrantly expressed in endometriosis 
regulate a wide range of cytokines and growth factors thought to be involved in the immunobiology 
of endometriosis including those referred to above.  For a summary of the factors regulated by 
miRNAs in endometriosis see Table 6.  
 
Gene Regulatory 
miRNA 
Expression in 
Endometriosis 
Source Consequence 
VEGF miR-126 
miR-195 
↓ 
↓ 
Pan et al Thought to be involved in the 
neovascularisation of endometriotic 
cells [409] 
P450arom miR-23a 
miR-23b 
↓ 
↓ 
Pan et al Involved in the production of excess 
estradiol promoting the proliferation of 
endometriotic cells [410] 
MMP-9 
 
miR-191 
miR-24 
↓ 
↓ 
Pan et al Thought to be involved in the 
increased invasive capacity of 
endometriotic cells [411] β-Catenin miR-100 ↑ Ohlsson 
Teague et al 
HOXA10 miR-29a 
miR-29c 
↓ 
↑ 
Pan et al 
Ohlsson 
Teague et al 
Thought to be involved in 
endometriosis associated sub-fertility 
[412] 
IL6 miR-126 
miR-22 
let-7i 
 
↓ 
↓ 
↓ 
Pan et al Alteration of the expression of these 
cytokines is thought to be responsible 
for the altered immune response in 
women with endometriosis, allowing a 
permissive environment for 
endometriotic cells [32] IL-8 miR-145 ↑ Ohlsson 
Teague et al 
TNFα miR-125b 
 
miR-10b 
↑ 
 
↓ 
Ohlsson 
Teague et al 
Pan et al 
INFγ miR-143 
miR-125b 
miR-24 
miR-29a 
miR-26b 
miR-27b 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
Pan et al 
TGF miR-23a ↓ Pan et al A potent effector of peritoneal 
adhesion formation in endometriosis 
[413] 
EGF miR-29a ↓ Pan et al Found to be significantly up regulated 
in late stage endometriosis, though to 
enhance proliferation of endometriotic 
cells [414] 
 
 
Table 6. Micro-RNAs in Endometriosis 
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3.4.3 Can Epigenetics explain the Malignant Potential of Endometriosis? 
The overall genetic and epigenetic similarities between endometriosis and cancer are summarised in 
Table 7 
 
 Endometriosis Cancer 
Monoclonal origin 
 
Inconclusive  
Down regulation of p53 
 
  
Down regulation of PTEN 
 
  
Over expression of c-myc 
 
  
Over expression of Bcl-2 
 
  
Loss of heterozygosity  
 
  
Chromosome 17 aneuploidy  
 
  
Up regulation of VEGF 
 
  
Over expression of CYP1A1 
 
  
Altered microRNA profiles 
 
  
DNMT over expression 
 
  
 
 
MiRNAs can act as tumour suppressors and oncogenes. Table 8 shows the relationship between 
specific miRNA expression in endometriosis and different cancer types. 
 
 
 
Table 7. Similarities between endometriosis and cancer 
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miRNA Expression 
in cancer 
(cancer 
type) 
Expression in 
Endometriosis 
Target gene/s References 
Potential tumour suppressors 
Let-7 (family) ↓ (lung) ↓ Ras [415, 416] 
miR-143 ↓ (breast) ↓ ERK5 [417-419] 
miR-145 ↓ (colorectal, 
breast) 
↓ 
miR-195 ↓ (various) ↓ Cyclin D1, CDK6, E2F3 [420] 
miR-1 ↓ (lung) ↑ MET [421] 
Potential oncogenes 
miR-21 ↑ (various) ↓ PTEN [422, 423] 
miR-221 ↑ (thyroid) ↓ KIT [424] 
miR-222 ↑ (thyroid) ↓ 
 
MiRNA 200a and 200b were identified as being down regulated in both endometriosis and ovarian 
clear cell and endometrioid cancer.  Table 9 shows the targets of both genes and the function of 
each target.  
 
 
 
 
 
 
Table 8. Comparison of miRNA expression in cancer and endometriosis 
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MiRNA-200a Targets 
Target name Function Reference 
ZEB2 Over expression of ZEB2 associated with ovarian cancer progression, 
poor prognosis and metastasis  
[425, 426] 
KLF12 Involved in cellular proliferation and invasive potential of cancerous 
cells 
[427] 
MiRNA-200b Targets 
ZEB2 See above [428] 
ZEB1 Over expression leads to the progression of ovarian cancer [429, 430] 
 
3.5 Discussion 
3.5.1 Insulin like Growth Factors and Imprinting 
The discovery of only two imprinted genes dysregulated in endometriosis may not appear 
significant, however, when taken into consideration that LOI only a single gene is required to 
produce deleterious effects [431-433], the case for LOI in endometriosis gains support. The role of 
ASB4 and BEGAIN in the aetiology of endometriosis has yet to be clarified. However, the function of 
each of these gene products may provide clues as to their role in endometriosis. ASB4 has been 
reported be involved in vascular differentiation [434], a process that is very important in the 
establishment of endometriotic implant blood supply, therefore the aberrant expression of ASB4 
may contribute to the vascularisation of endometriotic implants. More speculatively ASB4 has also 
been identified as a possible regulator of energy homeostasis [435]. Down regulation of this gene 
may therefore provide some explanation for the presentation of fatigue symptoms in women with 
endometriosis [436]. The influence of aberrant BEGAIN expression in endometriosis is more difficult 
to assess as this gene product is reportedly a member of the NMDA receptor associated proteins 
which is involved in the correct assembly of neuronal synapses [437]. Whether or not LOI is 
Table 9. MicroRNA-200a and 200b targets potentially involved in malignant transformation of endometriosis 
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responsible for the observed aberrant expression of imprinted genes ASB4, BEGAIN, WT1 or IGF-2 in 
endometriosis requires clarification, but it is an option that has never previously been considered.  
 
Given the evidence from diseases where LOI is a causative factor, it is unlikely that LOI is a causative 
factor for endometriosis. For example, diseases characterised by LOI (e.g. Angelman syndrome, 
Prader-Willi syndrome) are usually also characterised by obvious phenotypic abnormalities from 
birth or in infancy [438, 439] resulting from LOI in either the germline or embryonic cells. It is more 
likely from the evidence presented here that LOI, if occurring in endometriosis, is similar to LOI in the 
pathogenesis of cancer, i.e. a contributory factor rather than a causative one, meaning that LOI 
would occur later in life in fully differentiated somatic cells, possibly by disruption of the methylation 
state of the ICRs by an as yet unidentified mechanism. 
3.5.2 MicroRNA and Endometriosis 
The involvement of different immunological, hormonal and environmental factors comprises a 
complex web of interactions that play a major part in the pathophysiology of endometriosis, 
allowing the survival, proliferation and vascularisation of endometriotic implants.  Particularly 
important is the interplay between peritoneal macrophages and endometrial cells. Normally 
peritoneal macrophages (PM) suppress the proliferation and vascularisation of endometrial cells, 
however PM from women with endometriosis display a reverse effect, inducing endometrial cells to 
proliferate. The functions of PM are under the control of various cytokines and it has been 
postulated that aberrant expression of these cytokines and growth factors in endometriosis leads to 
altered PM function, creating a permissive environment in which endometrial cells can form 
endometriotic implants. For example, tumour necrosis factor (TNFα) is normally involved in the 
regulation of growth and shedding of the human endometrium and can enhance the production of 
prostaglandin by endometrial cells [440]. TNFα expression is also controlled by miRNAs (Table 6) and 
has been shown to promote inter-cellular adherence [40] possibly providing additional evidence as 
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to how refluxed endometrial cells attach themselves to the peritoneum. TNFα is a stimulatory factor 
for the production of Interleukin-8 (IL-8) and MMPs, which are thought to be involved in the invasion 
of endometriotic cells by increasing the adhesion of endometrial cells to fibronectin [441].   
Estradiol up-regulates IL-1β and is essential for the development of endometriosis. Epigenetic 
alterations such as the induction of aromatase and increased expression of estrogen receptors can 
lead to increased estradiol production and sensitivity in endometriotic cells. The knock on effect that 
estradiol exerts over IL-1β expression is confirmed by significantly increased IL-1β concentrations in 
patients with endometriosis [442]. IL-1β induces the secretion of IL-8, which contributes to cellular 
invasiveness [443].  
 
Estradiol is also known to up-regulate vascular endothelial growth factor (VEGF) [444], a potent 
angiogenic factor that is reportedly increased in patients with endometriosis [409, 445] and which is 
thought to regulate neovascularisation of endometriotic implants. VEGF expression is also under the 
control of miRNAs disrupted in endometriotic cells (Table 6). Not only are these cytokines involved in 
the survival, proliferation and vascularisation of endometriotic cells but contribute significantly 
towards the chronic pelvic pain associated with endometriosis, namely the formation of adhesions 
[446].  Adhesions can result from tissue damage caused by chronic inflammatory response or by 
surgery. IL-6 and TNFα in particular, have been identified as important for adhesion formation [447], 
both of which are under the control of miRNAs reported to be deregulated in endometriotic cells.   
Defects in both the classical and epigenetic mediators of transcription may interplay, leading to two 
completely different phenotypes arising from identical genotypes, it could also lead to the enhanced 
or repressed expression of genes involved in the pathogenesis of endometriosis, (Figure 30). Pan et 
al and Ohlsson Teague et al have provided the first definitive evidence for the involvement of 
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aberrant miRNA expression in endometriosis. Some of the possible effects of such disruption are 
summarised in Table 6. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 30. The effects of epigenetic mechanisms on gene expression 
In one state Gene A displays hypermethylation patterns in the CpG islands of its promoter (represented by blue circles). This in 
turn prevents or reduces binding affinity of the classical mediators of transcription such as transcription factors (TF), thus 
lowering or halting transcription of the gene. If any mRNA is synthesised, microRNAs with a complimentary sequence may bind 
to it. This signals that the mRNA be cleaved by proteins such as an endonuclease preventing the translation of the mRNA by the 
ribosome (RIB). This results in either a great reduction or complete silencing of gene expression. In the other state, methylation 
of the CpG islands is not maintained, possibly by environmental influences such as exposure to exogenous compounds or a 
methyl donor deficient diet. Binding of transcription factors like NF-κB is therefore permitted, thus transcription of the gene is 
enhanced. Reduced expression of microRNAs results in the mRNA of gene A remaining uncleaved and therefore translation of 
the mRNA by the ribosome occurs with less hindrance. This deregulation of the epigenetic modifiers of gene expression in 
endometriosis could possibly be an explanation for the up and down regulation of some genes observed in endometriotic cells. 
This is only a hypothetical model, however if Gene A were a key gene in a process such as regulating the cell cycle or invasive 
capability it can be seen how endometriotic cells acquire their characteristics from epigenetic abnormalities. This also 
demonstrates how two very different expression patterns can be established with no alteration to Gene A’s DNA sequence.  
 
Epigenetic Repression 
Unhindered Expression 
Gene A 
Gene A 
Gene A 
Gene A 
TF 
TF 
miRNA targeted 
degradation 
mRNA 
mRNA 
RIB 
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MicroRNAs also offer the possibility of novel therapeutic interventions for the treatment of 
endometriosis. MicroRNA therapy has already been proposed as a possible new method of the 
treatment of a range of diseases such as cancer and viral illnesses [448] but at present, this therapy 
is in the early developmental stages. The basic premise of miRNA therapy is that, if the miRNAs 
essential for the progression or initiation of a particular disease are known, then it may be possible 
to create complimentary anti-miRNA strands that would bind to the target miRNA thus, decreasing 
its ability to regulate gene expression. This would be of particular interest for regressing 
endometriosis. For example, if it were possible to target anti-miRNA strands to endometriotic cells, 
rendering their ability to express target genes such as the estrogen receptor, aromatase or anti 
apoptotic genes, these cells would be stimulated to undergo atrophy. However, this approach 
should be met with caution since a single miRNA may regulate many genes, thus the possibility of 
miRNA therapy disrupting non-target genes with unwanted effects must be considered.   
3.5.3 Can Epigenetic Aberrations explain the Malignant Potential of Endometriosis? 
Deepening of our understanding of the role of epigenetic mechanisms in human cancers has 
uncovered novel roles for miRNAs in the involvement of cancer origin and progression. In particular 
the ability of certain miRNAs to regulate genes involved in cellular proliferation, apoptosis and 
transcriptional regulation has led to them being considered equivalent to oncogenes and tumour 
suppressors [396, 449]. Recent studies of miRNA expression patterns of endometriosis allows 
comparative analysis with cancer miRNA patterns (Table 8). 
 
Certain similarities can be observed between the miRNA expression of endometriosis and cancer. 
For example, several tumour suppressor miRNAs are down regulated in malignant cells and 
endometriotic cells. Conversely, up regulation of oncogenic miRNAs associated with malignancies 
does not appear to match the miRNA expression in endometriosis.  It may be that a change in 
oncogenic miRNA expression contributes to malignant transformation of endometriosis. Comparing 
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cancer in general to endometriosis is however erroneous, as only certain cancer types are associated 
with endometriosis, most notably ovarian cancer. Both endometrioid and clear cell carcinoma of the 
ovary have been identified as arising from endometriosis [365, 450-452]. MiRNA-200a and miRNA-
200b are reportedly down regulated in endometrioid and clear cell ovarian cancer [397, 453, 454] as 
well as endometriosis [358], offering a novel perspective on miRNA-200a and 200b as potential 
mediators of malignant transformation of ovarian endometriosis. Analysis of the predicted targets of 
miRNA-200a and 200b give clear indications to their role in carcinogenesis from endometriosis 
(Table 9). Importantly their targets ZEB1 and ZEB2 are involved to the epithelial-mesenchymal 
transition (EMT) [455, 456], a process that is characterised by the loss of adhesion molecule 
expression and increased metastasis. It is important to note that several of the adhesion molecules 
that are under expressed as a result of EMT in cancer are also under expressed in patients with 
endometriosis [457, 458]. Not only is this an important factor for the metastatic spread of cancerous 
cells but it may also explain observations of endometriotic cells appearing at distant sites around the 
body, possibly by lymphatic transport [459, 460]. Therefore, progressive down regulation of 
miRNA200a and 200b may induce the transformation of ovarian endometriosis to cancerous tissue 
via the activation of their target genes which induce the already unstable endometriotic cells into a 
state of malignancy.  
 In conclusion, epigenetic aberrations reported in endometriosis may provide novel explanations for 
the mechanisms by which endometriosis can undergo malignant transformation. Aberrant DNA 
methylation and altered miRNA profiles may ‘prime’ endometriotic cells for transformation by 
imbuing these cells with increased proliferation and resistance to apoptosis.  However, far more 
studies are needed to assess the epimutational steps that separate endometriosis and cancer.  It 
may be that a certain sub-type of ovarian cancer exists which can only originate from ovarian 
endometriosis. However, more detailed histological and molecular analysis of ovarian cancer found 
in close proximity to ovarian endometriosis would be required.   
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4. Concluding Remarks and Future Directions 
 
Throughout this thesis various novels concepts have been addressed with the aim of gaining a better 
understanding of the mechanisms underlying the development and progression of endometriosis. 
Predicting the prevalence of endometriosis using known risk factors is, in itself, a novel concept that 
yielded some interesting results. To date the true prevalence of endometriosis can only be estimated 
for a handful of countries. Presently there is no non-invasive diagnostic test for endometriosis 
making it difficult to diagnose even in developed countries, therefore prevalence rates for under 
developed countries are likely to be inaccurate or simply non-existent. A prediction model, such as 
the one presented in this thesis is the first step towards understanding the global prevalence of the 
disease and the concurrence of the results obtained from the model with real world data solidify its 
accuracy. Further development of this model, using more sophisticated epidemiological methods 
and accurately weighting risk factors will allow for increased accuracy of the model with a further 
aim of allowing it to predict incident rates as a number per 1000 of the population. This will allow 
comparisons with data that exist in other countries.  Recently the World Endometriosis Research 
Foundation announced it will be conducting a prospective study to assess the incidence of 
endometriosis in 10 countries. This data will allow comparisons with the prediction model when it is 
completed in 2011. If it is found that the results generated by the model do indeed fit with real 
world data the most interesting results will come from countries that do not fit the model. Countries 
whose incidence rates do not fall within predicted parameters may offer novel insights into the 
epidemiology of endometriosis. An example analogous to this would be the French paradox, which 
states that the French population has a much lower incidence of heart disease than would be 
expected of a country with a diet so high in saturated fats. Although a satisfactory answer for this 
paradox has yet to be identified, some claim higher than average consumption of red wines may 
illicit a protective effect due to their polyphenol content.  
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Although very few studies have been conducted focussing on the involvement of epigenetics in the 
pathophysiology of endometriosis, it is clear that modified epigenetic states play a role in its 
pathogenesis. The over-expression of the DNMTs and aberrant expression of miRNAs appear to be 
the main contenders. These findings are in agreement with our current understanding of the disease 
and provide new insights into the aetiology of endometriosis. Examples of epigenetic involvement in 
endometriosis which have been illustrated include; the establishment of the aromatase positive 
feedback loop, the contribution of HOXA10 aberrations leading to the observed decreased fertility in 
endometriosis patients, and the implications that decreased miRNA expression may lead to immune 
system anomalies (Figure 31).  The involvement of aberrant epigenetic mechanisms may also 
enhance our understanding of the key hereditary features of endometriosis whilst highlighting its 
manifestation in the absence of any family history. If epigenetic (and genetic) changes predisposing 
endometriosis occur in-utero then endometriosis may be acquired through environmental factors, 
chemical exposure and dietary components in much the same way as in the initiation and 
progression of cancer. However, once these epigenetic changes are established they may then be 
passed onto future generations, increasing susceptibility to endometriosis.  
 
Epigenetics may also provide an insight into the way in which retrograde menstruation and coelomic 
metaplasia operate synergistically. For example, should the epigenetic changes occur in-utero, then 
they may prime the cells of developing mullerian duct or indeed, any other structure to possess 
what could be considered ‘pre-endometriotic’ cells (i.e. cells that, given the correct stimulus, may 
fully transform to become into endometriotic cells). The stimulus required for transformation of pre-
endometriotic cells into endometriotic cells may arise from refluxed menstrual effluence such as 
growth factors, cytokines and hormones. 
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Alterations in the functional development of the uterus as a result of epigenetic deregulation of the 
HOXA10 gene may predispose to higher volumes of menstrual reflux. Additionally, alteration of the 
epigenetic regulation of the immune system through the alteration of miRNA action may provide a 
permissive environment for endometriotic cell survival and proliferation. However, transformation 
may also result from developmental exposure to certain drugs or compounds that increase levels of 
mitogenic hormones, such as dioxin or DES. This would explain how non-menstruating women and 
men can develop an endometriosis like phenotype.  
Pre-existing Genetic 
Mutation 
Over expression of 
DNMTs 
Exposure to epigenetic 
modifiers in utero e.g. DES, 
toxicants, dietary factors  
 
Alteration of gene 
expression 
Alteration of Micro-
RNA expression 
Hereditary genetic 
/epigenetic changes 
Altered uterine 
morphology 
Altered hormone 
synthesis 
Decreased immune 
surveillance 
Increased menstrual 
reflux 
Survival, invasion and proliferation of endometriotic cells 
Figure 31. The interactions contributing to the pathogenesis of endometriosis 
Factors in blue represent established contributors to the aetiology of endometriosis, factors in red are the 
novel concepts that have been explored in this thesis 
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Epigenetics could also provide an interesting new approach for the treatment of endometriosis. 
Current therapeutic approaches are based on manipulation of the hormonal system, with varied 
success in relieving pain and restoring fertility. Therefore, utilising drugs that can correct epigenetic 
errors would be advantageous, whether alone or in combination with existing treatments for 
endometriosis. These drugs offer a promising new path to follow and have already been cited as a 
new addition to the arsenal of anti-cancer drugs. New epigenetic therapies for endometriosis could 
include alterations to diet and lifestyle since both play a major role in the establishment and 
maintenance of epigenetic states. The potential for dietary therapy for endometriosis based on 
restoring epigenetic marks may be an option worth consideration.  
 
Dysmenorrhoea is one of the most common symptoms of endometriosis. This intense pain 
commonly experienced by women is reportedly reduced by supplementation of the diet with fish 
oils [70], an effect which is enhanced by the addition of vitamin B12 [70]. Vitamin B12 is a major donor 
in the production of the methyl donor S-adenosyl methionine (SAM) and is therefore also important 
for maintaining methylation patterns. Whether or not the relief of dysmenorrhoea by a combination 
of fish oils and vitamin B12 is due to re-establishment of epigenetic marks (such as restoring the 
methylation state of hypomethylated genes) remains to be clarified.  A possible mechanism for the 
manifestation of dysmenorrhoea is the over production of prostaglandins [461], which may be 
stimulated by epigenetic hypomethylation in endometriosis as illustrated in the aromatase cycle 
(Figure 20). It could be postulated that supplementing the diet with vitamin B12 or other methyl 
donors may partially, or completely, restore the methylation patterns of the aromatase and/or SF-1 
gene and thus, reduce production of prostaglandins, hence alleviating dysmenorrhoea.  Potential 
dietary benefits that may result in the suppression of endometriosis and its symptoms may also 
come from phytologically derived isoflavones such as genistein. Supplementation of the diet with 
genistein has been shown to regress endometriosis in rat models. This regression is thought to occur 
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via the effect genistein has on epigenetic states. For example, genistein has been shown reactivate 
epigenetically silenced tumour suppressor genes such as p53 (which is down regulated in 
endometriosis) in prostate cancer cells [462] via the induction of histone acetylation and 
demethylation. If p53 function can be restored in endometriotic cells via the same mechanism, this 
may decrease the proliferative nature of endometriotic cells.  
 
There is no doubt that there are much more exciting discoveries to be made regarding the 
involvement of epigenetics in endometriosis. Further lines of investigation will endeavour to answer 
the following questions:  
 
• What are the methylation profiles of the CpG islands and histones of ectopic and eutopic 
endometrial cells from women with endometriosis? 
• What are the consequences of exposure to certain environmental factors on the epigenetic 
marks in women with endometriosis? 
• What effect does exposure to dioxin and other environment factors have on the progeny of 
those exposed? 
• Could demethylating agents such as 5-aza-2’-deoxycytidine be used for the treatment of 
endometriosis? 
• Can epigenetic alterations precede malignant transformation of endometriotic cells? 
• Is loss of imprinting a contributory factor to the pathophysiology of endometriosis? 
• Can epigenetic biomarkers (such as methylation patterns or miRNA signatures) be used for 
diagnosis or identifying those at risk of developing endometriosis? 
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Appendix 1 
 
Country Fertility – Avg 
children per 
woman. 
Source WHO 
(2004) 
Meat vs Plant Ratio – 
Consumption in 
g/capita/day. Source 
FAO (2001-2003) 
% Population In 
Urban Areas 
Source WHO (2005) 
Alcohol 
consumption – 
Kg/capita/yr. 
Source FAO(2003) 
Ovarian Cancer 
– Incidence rates 
per 100,000. 
Source 
Globocan (2002) 
Afghanistan 7.4 - 24.3 - - 
Albania 2.2 - 45.0 17 - 
Algeria 2.5 9.08 60.0 3 3.7 
Andorra 1.3 - 91.3 - - 
Angola 6.7 11.43 37.2 26 4.5 
Argentina 2.3 2.19 90.6 66 8.0 
Armenia 1.3 4.92 64.1 4 8.9 
Australia 1.7 2.07 92.7 112 8.9 
Austria 1.4 2.07 65.8 154 12.9 
Azerbaijan 1.8 5.98 49.9 24 8.7 
Bangladesh 3.2 31.37 25.0 0 3.4 
Belarus 1.2 2.72 71.6 33 11.5 
Belgium 1.7 2.18 97.3 131 12.0 
Belize 3.1 3.68 48.6 38 3.1 
Benin 5.7 - 46.1 14 - 
Bhutan 4.2 - 9.1 - - 
Bolivia 3.8 5.45 64.4 25 8.1 
Bosnia and Herzegovina 1.3 - 45.3 54 - 
Botswana 3.1 5.17 52.5 36 4.7 
Brazil 2.3 3.69 84.2 45 7.0 
Brunei Darussalam 2.4 - 77.6 1 - 
Bulgaria 1.2 3.19 70.5 53 10.0 
Burkina Faso 6.6 21.62 18.6 60 2.2 
 x 
 
Country Fertility – Avg 
children per 
woman. 
Source WHO 
(2004) 
Meat vs Plant Ratio – 
Consumption in 
g/capita/day. Source 
FAO (2001-2003) 
% Population In 
Urban Areas 
Source WHO (2005) 
Alcohol 
consumption – 
Kg/capita/yr. 
Source FAO(2003) 
Ovarian Cancer 
– Incidence rates 
per 100,000. 
Source 
Globocan (2002) 
Burundi 6.8 - 10.6 72 - 
Cambodia 4.0 9.33 19.7 3 3.4 
Cameroon 4.5 15.44 52.9 40 5.7 
Canada 1.5 2.74 81.1 91 11.6 
Central African Republic 4.9 - 43.8 17 - 
Chad 6.7 - 25.8 3 - 
Chile 2.0 3.44 87.7 44 7.8 
China 1.7 3.95 40.5 27 3.2 
Colombia 2.6 5.17 77.4 18 10.1 
Comoros 4.7 - 36.3 1 - 
Congo 6.3 16.56 54.4 19 2.1 
Costa Rica 2.2 4.13 61.7 20 6.0 
Côte d'Ivoire 4.9 24.64 45.8 17 4.9 
Croatia 1.3 3.78 59.9 128 14.4 
Cuba 1.6 7.70 76.0 27 4.7 
Cyprus 1.6 - 69.5 69 7.5 
Czech Republic 1.2 2.86 74.5 176 14.3 
Democratic People's Republic of Korea 2.0 - 61.7 8 - 
Democratic Republic of the Congo 6.7 45.57 32.7 20 2.1 
Denmark 1.8 1.53 85.5 131 14.2 
Djibouti 4.9 - 84.6 4 - 
Dominican Republic 2.7 5.86 60.1 45 3.3 
Ecuador 2.7 4.74 62.8 15 6.1 
Egypt 3.2 12.51 42.3 1 1.0 
El Salvador 2.8 6.76 60.1 20 4.5 
Equatorial Guinea 5.9 - 50.0 - - 
Eritrea 5.4 - 20.8 5 - 
Estonia 1.4 2.76 69.6 97 14.2 
Ethiopia 5.7 19.15 16.2 9 7.3 
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Finland 1.7 1.70 60.9 105 10.3 
France 1.9 1.68 76.7 93 9.7 
Gabon 3.9 5.95 85.2 80 6.6 
Gambia 4.6 17.18 26.1 31 1.8 
Georgia 1.4 4.85 51.5 11 6.6 
Germany 1.3 2.33 88.5 139 12.0 
Ghana 4.2 - 46.3 21 - 
Greece 1.2 3.49 61.4 64 8.7 
Guatemala 4.5 - 47.2 7 - 
Guinea 5.8 26.60 36.5 2 4.3 
Guinea-Bissau 7.1 - 35.6 18 - 
Guyana 2.2 5.66 38.5 21 6.5 
Haiti 3.9 12.72 38.8 11 1.9 
Honduras 3.6 - 46.4 17 - 
Hungary 1.3 2.21 65.9 114 11.1 
Iceland 2.0 1.45 93.0 64 17.0 
India 3.0 11.25 28.7 1 4.9 
Indonesia 2.3 21.65 47.9 0 8.1 
Iran (Islamic Republic of) 2.1 9.32 68.1 0 2.3 
Iraq 4.7 - 66.8 - - 
Ireland 1.9 2.10 60.4 211 13.8 
Israel 2.8 3.97 91.7 16 8.6 
Italy 1.3 2.87 67.5 79 9.3 
Jamaica 2.4 - 52.2 22 4.7 
Japan 1.3 3.38 65.7 49 6.4 
Jordan 3.4 7.93 79.3 2 3.5 
Kazakhstan 1.9 2.77 55.9 24 10.0 
Kenya 5.0 7.15 41.6 11 6.5 
Kuwait 2.3 3.66 96.4 0 6.2 
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Kyrgyzstan 2.6 4.01 33.7 10 10.1 
Lao People's Democratic Republic 4.7 - 21.6 17 - 
Latvia 1.3 2.73 65.9 65 14.0 
Lebanon 2.3 5.26 88.0 10 5.4 
Lesotho 3.5 21.91 18.2 29 3.2 
Liberia 6.8 - 47.9 6 - 
Libyan Arab Jamahiriya 2.9 - 86.9 0 - 
Lithuania 1.3 3.19 66.6 95 16.6 
Luxembourg 1.7 - 92.4 - 12.7 
Madagascar 5.3 - 27.0 8 - 
Malawi 6.0 37.30 17.2 15 1.8 
Malaysia 2.8 4.52 65.1 5 8.4 
Maldives 4.1 - 29.7 8 - 
Mali 6.8 10.10 33.7 5 2.0 
Malta 1.5 - 92.1 44 10.9 
Mauritania 5.7 - 64.3 0 - 
Mexico 2.3 4.25 76.0 49 7.4 
Monaco 1.8 - 100.0 - - 
Mongolia 2.4 1.69 57.0 12 3.7 
Morocco 2.7 13.22 58.8 3 3.4 
Mozambique 5.4 42.84 38.0 4 2.9 
Myanmar 2.3 20.25 30.6 0 4.8 
Namibia 3.8 4.86 33.5 11 3.5 
Nepal 3.6 - 15.8 0 - 
Netherlands 1.7 1.90 66.8 102 12.2 
New Zealand 2.0 2.09 86.0 94 12.4 
Nicaragua 3.2 8.48 58.1 14 6.9 
Niger 7.8 16.09 23.3 0 6.4 
Nigeria 5.7 30.36 48.3 72 3.2 
 xiii 
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Norway 1.8 1.95 80.5 72 13.9 
Oman 3.6 - 78.6 - 5.3 
Pakistan 4.1 4.47 34.8 0 9.8 
Panama 2.7 3.20 57.8 49 6.6 
Papua New Guinea 3.9 - 13.2 - 5.7 
Paraguay 3.8 4.25 58.5 50 7.5 
Peru 2.8 6.78 74.6 29 8.7 
Philippines 3.1 5.94 62.6 15 11.6 
Poland 1.2 2.89 62.0 88 12.5 
Portugal 1.5 2.43 55.6 124 8.6 
Qatar 2.9 - 92.3 - 6.5 
Republic of Korea 1.2 5.79 80.8 69 5.7 
Republic of Moldova 1.2 5.35 46.3 42 7.4 
Romania 1.3 3.79 54.7 85 9.4 
Russian Federation 1.3 3.54 73.3 69 9.1 
Rwanda 5.6 30.01 21.8 49 8.8 
Saint Lucia 2.2 - 31.3 61 - 
Saudi Arabia 3.9 5.92 88.5 0 4.5 
Senegal 4.9 9.81 51.0 4 4.4 
Serbia and Montenegro 1.6 - 52.3 75 - 
Sierra Leone 6.5 - 40.2 44 - 
Singapore 1.3 - 100.0 - 11.1 
Slovakia 1.2 3.14 58.0 103 12.4 
Slovenia 1.2 2.08 50.8 82 10.6 
Solomon Islands 4.2 - 17.1 1 - 
Somalia 6.3 - 35.9 - - 
South Africa 2.8 6.94 57.9 87 5.4 
Spain 1.3 2.60 76.7 106 9.9 
Sri Lanka 1.9 14.68 21.0 1 9.0 
 xiv 
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Sudan 4.3 3.94 40.8 0 4.3 
Suriname 2.6 6.75 77.2 45 6.0 
Swaziland 3.8 6.95 23.9 64 3.1 
Sweden 1.7 1.94 83.4 77 11.4 
Switzerland 1.4 1.92 67.5 102 12.4 
Syrian Arab Republic 3.3 - 50.3 0 - 
Tajikistan 3.7 9.84 24.2 1 7.0 
Thailand 1.9 6.75 32.5 35 5.6 
The former Yugoslav Republic of 
Macedonia 
1.5 4.43 59.7 50 9.2 
Togo 5.2 - 36.3 14 - 
Tunisia 1.9 8.31 64.4 1 2.7 
Turkey 2.4 8.79 67.3 11 4.8 
Turkmenistan 2.7 4.19 45.8 7 9.3 
Uganda 7.1 16.18 12.4 133 5.9 
Ukraine 1.1 4.23 67.3 44 10.9 
United Arab Emirates 2.5 - 85.5 - 4.1 
United Kingdom 1.7 2.36 89.2 124 13.4 
United Republic of Tanzania 4.9 14.53 37.5 67 4.0 
United States of America 2.0 2.67 80.8 98 10.6 
Uruguay 2.3 2.21 93.0 48 8.7 
Uzbekistan 2.7 4.77 36.4 6 8.2 
Venezuela (Bolivarian Republic of) 2.7 5.21 88.1 77 5.9 
Viet Nam 2.3 7.60 26.7 9 4.2 
Yemen 6.0 13.04 26.3 0 2.8 
Zambia 5.5 18.86 36.5 27 4.1 
Zimbabwe 3.4 11.40 35.9 25 7.2 
 xv 
 
Appendix 2 
 
Country 
Mean age  
at menarche 
(years)  
Age at 
menarche 
Year HDI Score 
HDI 
Year 
Algeria 14.30 1993 0.672 1995 
Argentina 12.59 1995 0.836 1995 
Australia 13.00 1998 0.949 2000 
Bangladesh  15.80 1993 0.453 1995 
Belgium  13.00 1984 0.883 1985 
Britain 13.30 1986 0.87 1985 
Cameroon  14.61 1985 0.523 1985 
Chile 13.00 1998 0.845 2000 
China 12.38 1997 0.691 2000 
Columbia 12.80 1991 0.729 1990 
Congo-Brazza 12.00 1992 0.559 1990 
Congo-Kinshasa 13.83 1984 0.43 1985 
Denmark 13.00 1998 0.935 2000 
Dominican republic 12.60 1990 0.697 1990 
Egypt 13.20 1978 0.482 1980 
Finland 13.20 1984 0.884 1985 
France 13.05 1979 0.872 1980 
Germany (east) 14.00 1998 0.928 2000 
Ghana 13.98 1989 0.517 1990 
Greece 12.00 1984 0.869 1985 
Guatemala 13.75 1995 0.626 1995 
Haiti 15.37 1995 0.487 1995 
Hungary 12.90 1993 0.817 1995 
Iceland 13.06 1978 0.89 1980 
India (Punjab) 14.31 1980 0.45 1980 
Indonesia 13.00 1990 0.626 1990 
Ireland 13.52 1986 0.851 1985 
Israel 13.29 1982 0.83 1980 
Italy 12.20 1992 0.892 1990 
Jamaica 13.10 1988 0.713 1990 
Japan 12.50 1986 0.899 1985 
Kenya 14.40 1987 0.534 1985 
Malaysia 14.20 1985 0.696 1985 
Mexico 12.40 1993 0.786 1995 
Morocco 13.75 1996 0.581 1995 
Mozambique 13.20 2000 0.375 2000 
Nepal (high altitude) 16.20 1983 0.38 1985 
New Zealand 12.90 1994 0.908 1995 
Nicaragua 14.00 1971 0.583 1975 
Nigeria 15.00 1998 0.445 2000 
Norway 13.20 1995 0.938 1995 
Papua New Guinea 15.80 1992 0.495 1990 
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Country 
Mean age  
at menarche 
(years)  
Age at 
menarche 
Year HDI Score 
HDI 
Year 
Peru 13.23 1988 0.71 1990 
Philippines 13.60 1988 0.721 1990 
Poland 13.06 1982 0.806 1990 
Portugal 12.03 2003 0.897 2005 
Romania 13.47 1967 0.786 1980 
Russia 13.00 1997 0.782 2000 
Senegal 16.10 1997 0.473 2000 
South Korea 13.90 1986 0.785 1985 
Spain 12.31 1997 0.932 2000 
Sri Lanka 13.50 1983 0.683 1985 
Sudan 13.75 1983 0.4 1985 
Sweden 13.09 1976 0.872 1975 
Switzerland 13.00 1996 0.926 1995 
Tanzania 15.21 1971 0.421 1990 
Thailand 12.30 1997 0.761 2000 
Turkey 13.28 1996 0.717 1995 
United States 12.80 1991 0.919 1990 
Venezuela 12.68 1981 0.737 1980 
Yemen 14.40 1979 0.402 1990 
Zambia 13.70 1980 0.478 1980 
Zimbabwe 13.50 1995 0.613 1995 
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Appendix 3 
 
 
Rank Score 
Country Fertility 
Plant vs Meat 
consumption 
Ratio 
% in Urban 
Environment 
Alcohol 
Consumption 
Ovarian 
Cancer 
Total 
score ERI 
Algeria 4 3 3 1 2 13 0.52 
Angola 2 2 2 2 2 10 0.4 
Argentina 4 5 5 4 3 21 0.84 
Armenia 4 4 4 1 3 16 0.64 
Australia 4 5 5 5 3 22 0.88 
Austria 4 5 4 5 5 23 0.92 
Azerbaijan 4 4 3 2 3 16 0.64 
Bangladesh 3 1 2 1 2 9 0.36 
Belarus 4 5 4 2 4 19 0.76 
Belgium 4 5 5 5 5 24 0.96 
Belize 3 4 3 2 2 14 0.56 
Bolivia 3 4 4 2 3 16 0.64 
Botswana 3 4 3 2 2 14 0.56 
Brazil 4 4 5 3 3 19 0.76 
Bulgaria 4 4 4 3 4 19 0.76 
Burkina Faso 2 1 1 3 1 8 0.32 
Cambodia 3 3 1 1 2 10 0.4 
Cameroon 3 1 3 2 2 11 0.44 
Canada 4 5 5 5 4 23 0.92 
Chile 4 4 5 3 3 19 0.76 
China 4 4 3 2 2 15 0.6 
Colombia 4 4 4 1 4 17 0.68 
Congo 2 1 3 1 1 8 0.32 
Costa Rica 4 4 4 2 3 17 0.68 
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Country Fertility 
Plant vs Meat 
consumption 
Ratio 
% in Urban 
Environment 
Alcohol 
Consumption 
Ovarian 
Cancer 
Total 
score ERI 
Côte d'Ivoire 3 1 3 1 2 10 0.4 
Croatia 4 4 3 5 5 21 0.84 
Cuba 4 3 4 2 2 15 0.6 
Czech Republic 4 5 4 5 5 23 0.92 
Democratic Republic of the Congo 2 1 2 1 1 7 0.28 
Denmark 4 5 5 5 5 24 0.96 
Dominican Republic 4 4 4 3 2 17 0.68 
Ecuador 4 4 4 1 3 16 0.64 
Egypt 3 2 3 1 1 10 0.4 
El Salvador 4 3 4 1 2 14 0.56 
Estonia 4 5 4 5 5 23 0.92 
Ethiopia 2 1 1 1 3 8 0.32 
Finland 4 5 4 5 4 22 0.88 
France 4 5 4 5 4 22 0.88 
Gabon 3 4 5 4 3 19 0.76 
Gambia 3 1 2 2 1 9 0.36 
Georgia 4 4 3 1 3 15 0.6 
Germany 4 5 5 5 5 24 0.96 
Greece 4 4 4 4 3 19 0.76 
Guinea 2 1 2 1 2 8 0.32 
Guyana 4 4 2 2 3 15 0.6 
Haiti 3 2 2 1 1 9 0.36 
Hungary 4 5 4 5 4 22 0.88 
Iceland 4 5 5 4 5 23 0.92 
India 3 2 3 1 2 11 0.44 
Indonesia 4 1 3 1 3 12 0.48 
Iran (Islamic Republic of) 4 3 4 1 1 13 0.52 
Ireland 4 5 4 5 5 23 0.92 
Israel 4 4 5 1 3 17 0.68 
Italy 4 5 4 4 4 21 0.84 
Japan 4 4 4 3 3 18 0.72 
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Country Fertility 
Plant vs Meat 
consumption 
Ratio 
% in Urban 
Environment 
Alcohol 
Consumption 
Ovarian 
Cancer 
Total 
score ERI 
Jordan 3 3 4 1 2 13 0.52 
Kazakhstan 4 5 3 2 4 18 0.72 
Kenya 2 3 3 1 3 12 0.48 
Kuwait 4 4 5 1 3 17 0.68 
Kyrgyzstan 4 4 2 1 4 15 0.6 
Latvia 4 5 4 4 5 22 0.88 
Lebanon 4 4 5 1 2 16 0.64 
Lesotho 3 1 1 2 2 9 0.36 
Lithuania 4 4 4 5 5 22 0.88 
Malawi 2 1 1 1 1 6 0.24 
Malaysia 4 4 4 1 3 16 0.64 
Mali 2 2 2 1 1 8 0.32 
Mexico 4 4 4 3 3 18 0.72 
Mongolia 4 5 3 1 2 15 0.6 
Morocco 4 1 3 1 2 11 0.44 
Mozambique 2 1 2 1 1 7 0.28 
Myanmar 4 1 2 1 2 10 0.4 
Namibia 3 4 2 1 2 12 0.48 
Netherlands 4 5 4 5 5 23 0.92 
New Zealand 4 5 5 5 5 24 0.96 
Nicaragua 3 3 3 1 3 13 0.52 
Niger 1 1 2 1 3 8 0.32 
Nigeria 2 1 3 4 2 12 0.48 
Norway 4 5 5 4 4 22 0.88 
Pakistan 3 4 2 1 3 13 0.52 
Panama 4 4 3 3 3 17 0.68 
Paraguay 3 4 3 3 3 16 0.64 
Peru 4 3 4 2 3 16 0.64 
Philippines 3 4 4 1 4 16 0.64 
Poland 4 5 4 5 5 23 0.92 
Portugal 4 5 3 5 3 20 0.8 
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Country Fertility 
Plant vs Meat 
consumption 
Ratio 
% in Urban 
Environment 
Alcohol 
Consumption 
Ovarian 
Cancer 
Total 
score ERI 
Republic of Korea 4 4 5 4 2 19 0.76 
Republic of Moldova 4 4 3 3 3 17 0.68 
Romania 4 4 3 5 4 20 0.8 
Russian Federation 4 4 4 4 4 20 0.8 
Rwanda 2 1 2 3 3 11 0.44 
Saudi Arabia 3 4 5 1 2 15 0.6 
Senegal 3 3 3 1 2 12 0.48 
Slovakia 4 4 3 5 5 21 0.84 
Slovenia 4 5 3 5 4 21 0.84 
South Africa 4 3 3 5 2 17 0.68 
Spain 4 5 4 5 4 22 0.88 
Sri Lanka 4 1 2 1 4 12 0.48 
Sudan 3 4 3 1 2 13 0.52 
Suriname 4 3 4 3 3 17 0.68 
Swaziland 3 3 2 4 2 14 0.56 
Sweden 4 5 5 4 4 22 0.88 
Switzerland 4 5 4 5 5 23 0.92 
Tajikistan 3 3 2 1 3 12 0.48 
Thailand 4 3 2 2 2 13 0.52 
The former Yugoslav Republic of 
Macedonia 4 4 3 3 4 18 0.72 
Tunisia 4 3 4 1 1 13 0.52 
Turkey 4 3 4 1 2 14 0.56 
Turkmenistan 4 4 3 1 4 16 0.64 
Uganda 1 1 1 5 2 10 0.4 
Ukraine 4 4 4 3 4 19 0.76 
United Kingdom 4 5 5 5 5 24 0.96 
United Republic of Tanzania 3 1 2 4 2 12 0.48 
United States of America 4 5 5 5 4 23 0.92 
Uruguay 4 5 5 3 3 20 0.8 
Uzbekistan 4 4 2 1 3 14 0.56 
 xxi 
 
Country Fertility 
Plant vs Meat 
consumption 
Ratio 
% in Urban 
Environment 
Alcohol 
Consumption 
Ovarian 
Cancer 
Total 
score ERI 
Venezuela (Bolivarian Republic of) 4 4 5 4 2 19 0.76 
Viet Nam 4 4 2 1 2 13 0.52 
Yemen 2 1 2 1 1 7 0.28 
Zambia 2 1 2 2 2 9 0.36 
Zimbabwe 3 2 2 2 3 12 0.48 
 
 
 
